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Abstract 
Background: Neo-adjuvant chemotherapy (NAC) results in physical deconditioning prior to 
high-risk surgery in patients diagnosed with oesophageal adenocarcinoma but remains the gold 
standard of care for patients with operable disease. Overall, physical and mental decline has 
been reported in patients, with a delayed return to baseline health-related quality of life 
(HRQL) following treatment. Exercise has been shown to improve fitness in patients undergoing 
non-cancer elective surgery. Furthermore, improved cancer control and immune function has 
been reported in exercising mice under laboratory conditions. Aim: The aim of this thesis is to 
examine the feasibility of a structured exercise prehabilitation program commencing prior to 
chemotherapy and continuing during treatment and the impact on outcomes for cancer 
patients. Methods: Patients were invited to participate in a clinical trial of exercise 
prehabilitation concomitant with standard care versus standard care alone. Following informed 
and written consent, patients were enrolled into the Pre-EMPT study and clinical data collection 
commenced. Post-operative tumour histopathology assessment was carried out according to 
Royal College of Pathology guidelines.   Cardiopulmonary exercise testing was performed during 
treatment. CT scans were assessed for body composition changes post-NAC. Immunity and 
Inflammatory bloods were assessed. HRQL was measured using validated patient reported 
outcomes. Results: A decline in patient fitness following NAC, measured by VO2peak, was 
blunted by 7% in patients undergoing the structured exercise prehabilitation program (-19% 
Control vs -12% Intervention). Overall length of hospital stay was lower than the national 
average in both groups, as were post-operative complications. Improved cancer control was 
evident in the Intervention group, measured by pathological evidence of disease regression in 
both primary tumour and lymph nodes. There was reversal of sarcopenic obesity with improved 
visceral /subcutaneous fat ratios in patients undergoing exercise prehabilitation. In addition, 
immune function was significantly improved with greater regulation of inflammatory markers 
(i.e. Interleukin-6). Overall mental wellbeing, measured using the Shortened Warwick-
Edinburgh Mental Well-Being Scale, was less perturbed in the Intervention group, also showing 
a recovery to baseline at 12 months after surgery. Conclusions: A structured exercise 
prehabilitation program during neo-adjuvant chemotherapy and prior to surgery is feasible and 
beneficial to patients with operable oesophageal adenocarcinoma. A structured exercise 
intervention reduces physical decline and improves cancer control in patients undergoing NAC. 
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Part A 
Chapter 1 Introduction 
 
1.1 Background 
From October 2011, I had the privilege of managing the research studies within the Upper 
Gastrointestinal (UGI) cancer surgery unit at St Thomas’ Hospital in London, United Kingdom 
(UK). 
Amongst others, we were involved in studies evaluating Health Related Quality of Life after 
oesophago-gastric surgery; genetically based blood, tissue and clinical outcomes collaboration 
with Professor Rebecca Fitzgerald’s group at Cambridge University; database studies assessing 
survival and recurrence in patients up to 10 years after surgery; novel measures of assessing 
comorbidities; internal audits of post-operative complications after surgery; and academic 
Bachelors, Masters and Doctoral thesis studies. 
Data collection of patients undergoing treatment within the UGI cancer surgery group was 
routinely collected, under ethical approval, for the purposes of review and research and as an 
integral part of the group’s efforts to improve the diagnosis, treatments and outcomes of 
patients after surgery.  
The surgical group also contributed data to the mandatory National Oesophago-gastric Cancer 
Audit (NOGCA).  
My career background in laboratory medicine, marketing management and product 
development in the pharmaceutical industry, and for the past 11 years in cancer research, 
equipped me well for the role of Clinical Research Manager within the Oesophago-gastric cancer 
surgery research group.  
In the first half of 2014, I was in the St Thomas’ theatre’s coffee room going through some 
research study material when Consultant Surgeon, James Gossage, suggested that I should 
undertake further study towards a higher educational degree - ‘as I was doing all the work but 
not being credited for it formally’. Initially, I dismissed his comment but as the next few months 
and years unfolded, and with the development of the Pre-EMPT study, I realised that if I could 
pull everything together it would be a great PhD thesis opportunity. The seed was planted. 
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1.2 Factors leading to the concept and development of the Pre-EMPT trial 
• Between April 2015 and March 2016, approximately 3000 patients’ surgical records of 
oesophageal and gastro-oesophageal resections were submitted to NOGCA. (Why do 
patients with a curative treatment plan for oesophago-gastric cancer not go on to receive 
surgery?, 2019).  
A topic of regular discussion and concern in this cohort of patients was, and continues to 
be, the high rate of post-operative complications after the high-risk surgery. 
Complications were measured using Clavien-Dindo scoring (Dindo, Demartines and 
Clavien, 2004; Clavien et al., 2009) and the NOGCA’s own scoring system. The Esophageal 
Complications Consensus Group (ECCG) was formed as an international group established 
to set a standardised format for recording of post-operative complications following 
oesophagectomy (Low et al., 2015) . In the 2017, a NOGCA report (Maynard et al., 2017) 
of the period April 2014 to March 2016, reported that 36.4% of patients were reported 
to have suffered complications after oesophagectomy (National Oesophago-Gastric 
Cancer Audit 2017, 2017). In-hospital mortality was 2.1% of patients operated with 90-
day mortality rates remaining high at 3.3%. 
Although patients went on to recover from their surgery and post-op complications, there 
was concern that complications after surgery for cancer of the oesophagus led to 
increased rates of recurrence and therefore reduced survival (Lagarde et al., 2008; 
Rutegård et al., 2012). 
• Health-Related Quality of Life (HRQL), at 3 years post-op, in these patients was worse 
than before surgery (Lagergren et al., 2007) and more recently, Swedish studies showed 
that complications after surgery had a major influence on HRQL for up to 10 years post-
surgery (Derogar et al., 2012; Kauppila et al., 2018) 
• Following the results of the MAGIC clinical trial (Cunningham et al., 2006a) which 
demonstrated that peri-operative chemotherapy (in the neo-adjuvant plus adjuvant 
settings) reduced tumour size, stage and improved rates of recurrence and survival in 
oesophageal cancer, the surgically-operable cohort of patients would undergo 
chemotherapy before surgery as standard-care. The downside of the introduction of neo-
adjuvant chemotherapy as standard-care in the United Kingdom (UK), from a surgery and 
recovery-after-surgery perspective, was the impact of chemotherapy-related 
deconditioning on the fitness (Navidi et al., 2018; Thomson et al., 2018) of patients 
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scheduled for invasive intra-thoracic/intra-abdominal surgery and the impact on post-
operative recovery, complications and HRQL. 
• Enhanced Recovery After Surgery (ERAS) programs, aiming to minimise operative stress, 
improve post-operative recovery and shorter hospital stay, were later introduced in 
patients undergoing oesophagectomy, due to the complexity of surgery and high rates of 
post-op complications (Liu et al., 2018). The main components of the ERAS programs were 
focussed on the immediate peri-operative period. The main benefits appeared limited to 
reduction of length of hospital stay rather than improvement in post-operative 
complications (Markar et al., 2017). 
 
As a group of clinicians and researchers, patient care and the improvement of diagnosis, 
treatment and outcomes was at the heart of our group’s research focus. The most significant 
development in the previous few years had improved tumour and survival outcomes but had led 
to reduction in patient fitness before surgery. Post-op morbidity remained stable but high and 
health-related quality of life was reduced for up to 10 years after surgery. What was the future 
for our research? 
In September 2014, Professor Greg Whyte was invited to address our oesophago-gastric cancer 
surgery research group. His presentation about fitness in relation to surgery and cancer 
stimulated discussion and consideration of developing pre-surgical physical/exercise 
optimisation of patients before major surgery. Some of the unanswered questions we had to 
consider were: Was exercise during neo-adjuvant chemotherapy feasible; was it safe; would it be 
beneficial physically and/or psychologically; might there be any ‘unknown’ outcomes?  
Pre-operative optimisation before surgery had been discussed and introduced in various contexts 
(Azhar, 2015; Meka et al., 2016)  but not, to our knowledge, in patients undergoing neo-adjuvant 
chemotherapy followed by surgery, in any cancer. 
In January 2015, we followed up Professor Whyte’s presentation with a visit to the team at the 
Centre for Health and Human Performance (CHHP), of which Prof Whyte is Co-founder and 
Director of Human Performance Science. This was a pivotal point in the forward development of 
this trial and thesis: “Feasibility of a structured exercise program in patients undergoing a 
‘curative’ pathway following a diagnosis of operable oesophageal adenocarcinoma”. The trial 
name Pre-EMPT was adopted: ‘Prehabilitation in patients diagnosed with oEsophageal 
Malignancy, on a Peri-operative Treatment pathway’ 
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We now had the essential ingredients: access to a suitable a patient group for the intervention; 
experts in clinical care in the relevant patient population, experts in physical performance and 
training, and in research practice; the necessary equipment and study locations.  
What we lacked was a suitable control cohort (the annual patient numbers would be too small 
for a Randomised Control Trial (RCT) at St Thomas’ Hospital alone); ethical approval, NHS 
approval, and of course, funding. 
 
1.3 Regulations and collaborators 
1.3.1 Developing a control cohort 
In March 2015, we approached Dr Mike Browning, Consultant Anaesthetist and Cardio-
pulmonary Exercise Testing (CPEX) Lead, at Maidstone and Tunbridge Wells NHS Hospitals 
(MTWH) to be Principle Investigator (PI) at MTWH.  
There were two main reasons for approaching Dr Browning in Maidstone: 
Firstly, he had a professional interest in pre-operative assessment using CPEX.  
Secondly, the patients at MTWH were a good geographical Control cohort – since 2015 all 
patients with operable oesophago-gastric cancer at MTWH were referred to St Thomas’ Hospital 
(STH) for cancer surgery; the patients received similar neo-adjuvant chemotherapy treatment at 
MTWH through online Multi-Disciplinary Discussion (MDM) with Guy’s and St Thomas’ NHS 
Foundation Trust (GSTT) Upper Gastro-intestinal Specialist MDM; Clinical Commissioning Groups 
(CCG) in Kent had requested a limit on patient travel to STH during the course of their treatment 
- largely for the purpose of minimising disruption to patients traveling long distances during their 
treatment. This made for a good, comparative, geographic control group for the study.  
All patients were to receive the standard-care treatment pathway with clinical, nursing, dietetic, 
physiotherapy and pre-op assessment that was in practice locally whether participating in the 
trial or not. 
 
1.3.2 Funding 
In collaboration with Chief Investigator and Consultant Upper Gastro-intestinal Surgeon at St 
Thomas’ Hospital, Mr Andrew Davies, I completed and submitted a funding application to the 
Guy’s and St Thomas’ Charity’s Health Innovation Funding scheme in May 2015. Unfortunately, 
the application was rejected. Following a further meeting with the Charity and a revised funding 
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application, we were successful in obtaining enough funding to run a 3-year Pre-EMPT clinical 
trial. 
CHHP generously offered to donate funding and staff to perform the CPEX testing and exercise 
training of patients in the Interventional cohort. Fitbit UK, donated Fitbit wearable trackers to 
monitor the patients in both Intervention and Control cohorts. Ultimately, data from the Fitbits 
would also provide information on heart rates and sleep patterns in patients undergoing neo-
adjuvant chemotherapy - another first in this group of patients. 
 
1.3.3 Research Ethics, Health Regulatory, NHS and R&D approvals 
With project and staff funding secured, I embarked on the unenviable task of dealing with the 
UK’s research ethics regulatory processes.  
I wrote the trial Protocol with full set of trial documents followed by the Integrated Research 
Application System’s (IRAS) online ethics application and documents. At the end of May 2016, 
the Health Regulatory Authority (HRA) added an additional level to the regulatory approvals 
process; however, this would assist by including the generic NHS approval prior to local site 
approval. 
As this study was not a ‘clinical trial of an investigative medical product’ (CTIMP) we were able to 
submit the study ethics application through the ‘Proportionate Review’ process – a shorter, 
potentially quicker process. 
In November 2016, we eventually received full Research Ethics Committee (REC), HRA, NHS and 
local GSTT Research and Development (R&D) approvals (Prehabilitation of Patients With 
oEsophageal Malignancy Undergoing Peri-operative Treatment - Full Text View - 
ClinicalTrials.gov). REC application number: 16/SC/0438 
5 days later we consented our first patient into the Interventional arm of the Pre-EMPT trial. 
It was a further few months until the trial was approved by the MTWH R&D department to start 
including patients in the Control cohort. The first control patient was consented in February 2017. 
 
1.4 PhD thesis registration 
Prof Greg Whyte OBE, Professor of Applied Sport and Exercise Science at Liverpool John Moore’s 
University (LJMU) and Co-Investigator on Pre-EMPT, kindly agreed to be Director of Studies for 
my PhD. 
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Pre-EMPT Chief Investigator and Consultant Surgeon, Andrew Davies and Dr Lynne Boddy, 
Reader in Children’s’ Physical Activity, kindly agreed to be Co-Supervisors. 
In October 2016, I enrolled as a PhD student at LJMU with the research proposal subsequently 
approved by the LJMU Research Degrees Committee. 
  
22 
 
 
Chapter 2  Cancer of the oesophagus and gastro-oesophageal junction cancer 
 
2.1 Epidemiology 
Oesophageal cancer (OC) is the 13th most common cause of cancer diagnosis, but the 7th most 
common cause of cancer death, in the United Kingdom (UK). In the UK, the one-year survival rate 
is around 42% falling sharply to 15% at 3 years after initial diagnosis (Oesophageal cancer risk | 
Cancer Research UK, no date). This sharp fall in survival is an indicator of the aggressive nature 
of the disease and the late presentation of patients for diagnosis and treatment.  
The prevalence is higher in men than in women (Oesophageal cancer risk | Cancer Research UK, 
no date) with the age-adjusted incidence in the UK rising by 39.6% for men and 37.5% for women 
every 5 years (Pennathur et al., 2013). The greatest incidence is in 70-74 year-old men 
(Esophageal cancer in England by age and gender | 2016 statistic ).  
Oesophageal cancer is divided largely into two main histological types: Squamous Cell Cancer 
(SCC) and Adenocarcinoma (AC). Over the past few decades, the incidence of AC has overtaken 
that of SCC in the UK, USA, Australia and some countries in Western Europe (Pennathur et al., 
2013). This histological change in AC is largely associated with an increase across all socio-
economic groups but especially in those with greater affluence (Lepage et al., 2008) and life-style 
factors including a diet low in fruit and vegetables, obesity, gastro-intestinal reflux disease, 
Barrett’s oesophagus (abnormal oesophageal cell growth), and tobacco use (Pennathur et al., 
2013) – many, largely related to a sedentary lifestyle. 
In this thesis, the focus is on patients diagnosed with the AC histological type. 
 
2.1.1 Diagnosis 
Patients present to their General Practitioner (GP) or to Accident and Emergency Departments 
with symptoms of pain or difficulty in swallowing (dysphagia), regurgitation after eating, 
vomiting, heartburn that does not go away, discomfort in the chest or back and / or weight loss 
(Signs and symptoms of oesophageal cancer - Understanding your diagnosis - Macmillan Cancer 
Support, no date). 
The initial investigations include an endoscopic oesophago-gastric-duodenoscopy (OGD) for 
visual, clinical examination with biopsies of any abnormal-looking areas for histological 
confirmation of disease. A Computerised Tomography Scan (CT) is carried out to assess tumour 
location, size and possible spread of disease to the surrounding organs. Depending on the 
outcome of these initial investigations, further evaluation of disease-spread may be carried out 
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by the patient undergoing a Positron Emission Tomography scan (PET) and staging laparoscopy. 
If metastases are suspected, further investigations may include Magnetic Resonance Imagining 
(MRI) and/or Fine-Needle Aspirate/Biopsy (FNA/B) of suspected tissue for histological 
confirmation. 
 
2.1.2 Staging 
On completion of all investigations, an expert Multidisciplinary Team Meeting (MDT or MDM) is 
convened and full details of each patient is presented for staging of the disease. The staging-
process assesses all the information available to decide on the location and TNM-stage of the 
disease (T.W. Rice et al., 2016) : 
T - stage provides information about the depth of tumour growing through the mucosal and 
deeper wall layers of the oesophagus or surrounding structures. 
N - stage informs about any nodal spread of disease. This may include spread to local or distant 
lymph nodes. 
M – stage is assessed by examining the whole body and potential spread of disease to any part 
of the body. 
This TNM value of the disease has an important bearing on the treatment pathway selected for 
a given patient. 
Location of the tumour is divided into upper-, mid-, lower- oesophagus or gastro-oesophageal 
junction. Location, in conjunction with the size, and containment or spread of disease, along with 
a patient’s comorbidities and fitness for treatment are the main parameters evaluated to plan a 
suggested course of treatment. These factors will influence any discussion with the patient about 
suitable treatments. 
 
2.1.3 Treatment 
In the UK, the standard treatment for patients diagnosed with operable, or locally advanced AC, 
are placed on a so-called ‘curatively-intended’ treatment pathway. The pathway includes neo-
adjuvant chemotherapy (or neo-adjuvant chemoradiotherapy in selected cases) followed by 
surgery. A further course of adjuvant treatment follows surgery in patients who are fit enough to 
resume oncological treatment after surgery and where the post-op histopathological assessment 
indicated the requirement for further oncological treatment. 
Patients who are deemed to have inoperable or metastatic disease, or who are deemed 
physically unfit for radical treatment are placed on a palliative treatment pathway. This pathway 
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will offer chemotherapy to those patients well enough to tolerate the toxicity of treatment side-
effects. Patients may be offered palliative radiotherapy for symptomatic control, artificial feeding 
or palliative stenting to support their nutrition and fluid requirements during treatment of ‘Best 
Supportive Care’. 
This thesis focuses on patients on a ‘curatively-intended’ treatment pathway. 
 
2.2 The ‘Curatively-intended’ Treatment Pathway 
2.2.1 Neo-adjuvant chemotherapy 
Patients on a treatment pathway of ‘curative intent’ undergo neo-adjuvant chemotherapy (NAC) 
to downstage the tumour size, lymph node burden and reduce micro metastases ahead of 
surgery, leading to an improved 5-year survival (Andrew R Davies et al., 2014).  
Patients undergoing NAC have 3 x 21-day cycles of anthracycline and platinum/fluoropyrimidine-
based triple therapy of Epirubicin (E), Cisplatin/Carboplatin (C) and 5-fluorouracil 
(5FU/F)/Capecitabine (X) (ECF/ECX) or those undergoing the more recently approved treatment 
regimen ‘FLOT’ which includes the addition of docetaxel combined with 
platinum/fluoropyrimidine therapy (Docetaxel, oxaliplatin, leucovorin and 5-fluorouracil), 
undergo 4 x 14-day cycles of treatment.  
Patients on an ECX/ECF treatment protocol, often experience toxicities that include vomiting, 
nausea, thromboembolic events and anaemia while those on a FLOT regimen experience more 
diarrhoea, infections, neutropenia, and sensory neuropathy (Bose et al., 2017). 
NAC treatment and side-effects have a deconditioning effect on patient-fitness which is further 
compounded by major surgery. 
  
2.2.2 Surgery and post-operative complications 
Oesophagectomy for cancer of the lower oesophagus or gastro-oesophageal junction involves 
removing most, or a large section of the thoracic oesophagus and about 1/3 to 1/2 of the 
stomach. 
The remaining stomach is refashioned into a pseudo-oesophagus/stomach with an intra-thoracic 
or cervical anastomosis to the remaining upper thoracic or cervical oesophagus. 
This is high-risk, invasive surgery and has historically had high mortality rates although these are 
now improving with centralisation of specialist services in high-volume centres (Low, 2013). Post-
operative complications, however, remain high and are associated with reduced survival 
(Rutegård et al., 2012). Reduced fitness is also associated with increased post-operative 
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morbidity (Levett and Grocott, 2015a) in oesophageal cancer surgery that involves transthoracic 
or transhiatal, two-cavity surgery. Reduction in fitness, compounded by NAC and major surgery, 
significantly reduces the numbers of patients who commence or complete the standard 
treatment of post-operative chemotherapy to around 40%. 
The combination of chemotherapy and surgery both represent significant physiological insults 
thought to have detrimental effects on physical activity and outcomes after surgery.  
 
2.2.3 Enhanced Recovery after Surgery 
Enhance Recovery after Surgery (ERAS) programs that focus on early post-operative mobilisation 
have helped to improve methods of pain-control and reduced-length of hospital stay. They have 
been introduced as standard-care in most UK oesophageal resection units. Analysis of ERAS-
standardised protocols have proven to be safe, resulting in a reduced length of hospital stay 
(Gatenby et al., 2015) and, in some cases, a reduction in non-surgical complications (Pisarska et 
al., 2017). 
To-date, however, the priority for improvement has been focused on the immediate peri-
operative and in-hospital recovery period. Little attention has been given to physical preparation 
for high-risk oesophageal surgery complicated by neo-adjuvant oncological therapies. 
 
2.2.4 Rehabilitation versus Prehabilitation 
Preparing patients for surgery through a program of exercise before surgery has been shown to 
improve functional recovery in patients undergoing cardiovascular and orthopaedic surgery 
(Debes, Aissou and Beaussier, 2014). Rehabilitation after cancer treatment has been successful 
in improving physical and psychological impairments, and quality of life (Fialka-Moser et al., 
2003). Increasingly, advanced exercise programmes, sometimes termed ‘prehabilitation’, 
directed by experienced multidisciplinary teams are  being used to mitigate the secondary effects 
of cancer treatment (Julie K Silver and Baima, 2013).  
To date, no data has been published examining structured exercise prehabilitation programs for 
patients undergoing neo-adjuvant chemotherapy and surgery in oesophageal cancers but, it was 
hypothesised that a program of supervised physical activity during neo-adjuvant oncological 
treatment would be feasible, would reduce chemotherapy-related deconditioning and improve 
physical fitness before surgery. 
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This thesis aimed to investigate the feasibility, and potential benefits, for patients undertaking a 
prescribed physical activity program starting before commencing NAC, continuing throughout 
NAC, with further consolidation of physical optimisation during the period leading up to surgery.   
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Chapter 3  Review of Literature 
 
The following chapter is based on an invited, published review article on prehabilitation in 
oesophageal cancer surgery (Zylstra et al., 2018). 
 
Prehabilitation 
“By failing to prepare, you are preparing to fail.”       
    Benjamin Franklin 
Delivery of care for patients with oesophageal cancer is no longer the preserve of single 
modality surgical intervention but has become a multifactorial ‘aggregation of marginal gains’ 
in multidisciplinary practice. This review aims to explore the benefits of exercise prehabilitation 
in oesophageal cancer treatment. 
 
Background 
The physiological impact of having an oesophagectomy is often likened to that of running a 
marathon. Whilst nobody would consider starting a marathon without months of dedicated 
preparation, the majority of patients scheduled for surgery undergo little or no physical training 
in the lead up to their operation.  
In recent years, Enhanced Recovery After Surgery Programs (ERAS/ERP) have resulted in 
improved short-term outcomes after surgery (Preston et al., 2013) and have widely been 
integrated into surgical-oncology pathways as best practice. Yet, increasing the expectations on 
patients recovering from high-risk surgery without preparing them physically makes little sense. 
In some disciplines, where pre-operative exercise programs have been introduced to optimise 
physical function in patients before surgery, a positive benefit on post-operative functional 
capacity and return to activities of daily living has been seen in the short-term(Carli, Gillis and 
Scheede-Bergdahl, 2017). Physical or multimodal prehabilitation of patients before 
cardiovascular, abdominal and colorectal cancer surgery has resulted in improved pre-and post-
operative functional capacity (Mayo et al., 2011; Debes, Aissou and Beaussier, 2014; Minnella et 
al., 2017; Steffens et al., 2018). However, the focus in these programs has been in the peri-
operative period. The opportunity for extended prehabilitation from the time of diagnosis, 
through neo-adjuvant oncological therapy, is the subject of a number of on-going clinical trials. 
(Table 1)  
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Current status in oesophago-gastric cancer 
In patients diagnosed with locally advanced oesophago-gastric cancers, neo-adjuvant 
chemotherapy (NAC) or chemo-radiotherapy (NACRT) followed by surgery remains the treatment 
of choice (Low et al., 2007; Chen et al., 2017; Zhou et al., 2020). Introduction of neo-adjuvant 
oncological therapies has resulted in improved overall and disease-free survival (Bosset et al., 
1997; Andrew R. Davies et al., 2014). However, the effects of neo-adjuvant chemotherapy result 
in physiological deconditioning. In a study using cardiopulmonary exercise (CPEX) testing before 
and after NAC, Jack et al recorded a 15% decline in oxygen uptake at estimated lactate threshold 
in patients due to undergo oesophago-gastric surgery (Jack et al., 2014; Thomson et al., 2018). 
Improvements in surgical techniques, including minimally invasive and robotic surgery, and 
centralisation of surgery to specialist centres have improved safety. As a result, the 30 day post-
operative mortality has reduced from 10.3% to 1.9%  in the UK national audit (Boddy, Williamson 
and Vipond, 2012; Maynard et al., 2017). ERAS programs have resulted in reduced length of stay 
and readmissions to hospital after surgery(Preston et al., 2013; Ashok et al., 2020). However, 
whilst mortality rates have fallen, reported post-operative morbidity rates of 36 – 59% (Gockel, 
Exner and Junginger, 2005; Booka et al., 2015; Low et al., 2017) and resolution of quality of life 
remain a significant challenge - both of which may conceivably be improved by prehabilitation. 
The demographic of patients being diagnosed with potentially ‘curable’ oesophageal cancer is 
also a changing landscape. With the ageing population, older patients on poly-pharmacy 
regimens are presenting with tumours that are technically surgically resectable but who are of 
borderline fitness for high-risk and physiologically demanding surgery. Profoundly unfit patients 
with comorbidities relating to sedentary lifestyles are also being seen with a cancer diagnosis at 
a young age. 
The health benefits of exercise are well established (Warburton, Nicol and Bredin, 2006).  These 
include lower mortality and morbidity rates (Paffenbarger et al., 1993; Sandvik et al., 1993), 
improved cardiovascular function, strength and muscle mass, postural stability and psychological 
function, improvements in depressive symptoms and sleep disorders(Butler et al., 1998) and 
better overall quality of life (Penedo and Dahn, 2005). With the safety and benefits of exercise 
during cancer treatment being accepted as a principle(Galvão and Newton, 2005; Witlox et al., 
2018) and encouraged by cancer support organisations (Benefits of being active - Information 
and support - Macmillan Cancer Support, no date), the focus of attention in oesophageal cancer 
has turned to prehabilitation before surgery, specifically encompassing the neo-adjuvant 
treatment period.  
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Heldens et al. (Heldens et al., 2016) reported on the feasibility of a structured exercise program 
during neo-adjuvant chemo-radiotherapy in patients diagnosed with rectal cancer. They 
concluded that an outpatient prehabilitation program was largely feasible and safe, and not only 
prevented the reduction in physical fitness decline associated with NACRT but improved 
functional exercise capacity by 9.0% and leg muscle strength by 39.2%. 
Pre-operative programs, focusing mainly on respiratory function, have shown mixed results 
across a variety of surgical disciplines, including cancer (Banugo and Amoako, 2017). Dettling et 
al. reported on the benefits of Inspiratory Muscle Training (IMT) as significantly improving 
respiratory muscle function but with no benefit on post-operative pneumonia following 
oesophagectomy (D S Dettling et al., 2013).  However Boden et al. reported a 50% reduction in 
postoperative pulmonary complications after major upper abdominal surgery following a single 
preoperative physiotherapy session (Boden et al., 2018). An increase in inspiratory muscle 
function but no increase in peripheral muscle strength or aerobic capacity using IMT, was 
reported by Valkenet at al. who suggested that the limited benefits were partly due to a short 
interval between screening and surgery (Valkenet et al., 2016). 
In a trial, which included pre-operative aerobic and resistance training versus rehabilitation in 
colorectal cancer patients, Gillis et al. reported similar hospital length of stay and post-operative 
outcomes (Gillis et al., 2014). However, there was an improvement in 6-min walk test (6MWT) in 
the prehabilitation group at 8 weeks after surgery when compared to the rehabilitation group, 
suggesting a better maintained physical capacity and/or accelerated recovery post-surgery 
following prehabilitation. 
 
Prehabilitation in surgery 
Tew et al.(Tew et al., 2018), in their ‘Clinical guidelines and recommendations on pre-operative 
exercise training in patients awaiting major non-cardiac surgery’, graphically represent the 
physical trajectory of prehabilitation before surgery with the anticipated post-surgery 
improvement in functional capacity, versus that of the non-optimised surgical patient (Figure 1). 
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Figure 3-1 The prehabilitation concept. (Tew et al., 2018). 
Printed with permission Copyright © 2018 The Association of Anaesthetists of Great Britain and 
Ireland  
 
A summary of their key recommendations on peri-operative exercise include:  
• Priority of patient selection, especially those identified with a higher risk of peri-operative 
complications   
• Multimodal interventions including: smoking cessation; reduction in alcohol intake; and 
treatment of anaemia 
• Presentation of the exercise program as pre-operative optimisation rather than as an 
optional extra 
• Initial patient assessment, including comorbidity optimisation, risk evaluation and 
education on the benefits of exercise 
• Objective functional evaluation and quality of life assessment 
• Ongoing ‘response to training’ functional assessments 
• Sufficient time for intervention, commencing as early in the surgical pathway as possible, 
ideally with a minimum of 4 weeks before surgery 
Copyright material removed for thesis 
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• A combination of aerobic training, resistance training and inspiratory muscle training, 
tailored to each patient 
• Supervised programs by trained individuals. Self-managed programs may be suitable in 
selected individuals. 
 
In an elective surgical patient group, these are valuable and important recommendations. 
However, there are challenges in following these guidelines within a cancer treatment pathway. 
Patient selection after a diagnosis of cancer is based largely on tumour-stage and patient fitness. 
With ‘time-to-treat’ targets and established cancer treatment pathway guidelines, there is little 
time for optimization of modifiable comorbidities and lifestyle factors particularly if these 
interventions are constrained to the narrow window between diagnosis and start of NAC. Patient 
fitness, in the majority of these patients, is already compromised. Cramer et al. found that, on 
average, colorectal cancer patients had a baseline VO2 peak of 23% below that of general 
population, age-matched controls (Cramer et al., 2014). To compound this, patients frequently 
develop induced complication toxicities from chemotherapeutic agents. Anthracyclines and anti-
angiogenic targeted therapies, commonly used in the neo-adjuvant pathway, lead to increased 
exercise intolerance in cancer patients (Jones et al., 2009; Bonsignore and Warburton, 2013).  In 
the UK MRC OE05 chemotherapy trial, 12% of patients stopped chemotherapy early due to 
toxicities and 11 % of patients did not proceed to surgery. Of these, 15% developed significant 
comorbidities that precluded surgery. The mortality from combined Epirubicin, Cisplatin and 
Capecitabine (ECX) chemotherapy was 1.8%, equivalent to the post-operative mortality seen in 
the trial (Alderson et al., 2017).   
Therefore, a diagnosis of cancer, and especially oesophageal cancer, results in a unique group of 
patients requiring an individualised or tailored approach to prehabilitation. This mandates a 
fundamental understanding of the treatments they receive and an appreciation that the exercise 
intervention may differ at the various stages of the treatment pathway.   
 
Prehabilitation in cancer 
Silver and Baima describe cancer prehabilitation as “a process on the cancer continuum of care 
that occurs between the time of cancer diagnosis and the beginning of acute treatment, includes 
physical and psychological assessments that establish a baseline function level, identifies 
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impairments, and provides targeted interventions that improve a patient’s health to reduce the 
incidence and the severity of current and future impairments” (Julie K. Silver and Baima, 2013a). 
Table 1 represents the current landscape of registered clinical trials of pre-operative exercise 
interventions in oesophageal cancer, focusing on those during NAC. They are limited to relatively 
small, prospective studies with numerous primary endpoints and large variations in how physical 
function is measured. 
Each study has been evaluated according to Silver’s definition of prehabilitation in cancer (Julie 
K. Silver and Baima, 2013a). The few studies that have reported results mainly include exercise 
interventions focusing on pre-operative respiratory muscle training with the aim of reducing 
post-operative pulmonary complications.   
The awaited results will help to inform and shape the future of UGI cancer prehabilitation.  
A number of important points are highlighted from the Silver’s description that present 
challenges that need to be met in any attempt to successfully deliver prehabilitation in cancer 
patients: 
1. A process on the cancer continuum of care 
A continuum is ‘A continuous sequence in which adjacent elements are not perceptibly different 
from each other, but the extremes are quite distinct.’ (Oxford Living Dictionaries, 2017) 
In the context of the cancer patient, the investigative and treatment pathways may feel like a 
continuum. However, in reality, there are distinct needs during each element from diagnosis, 
through chemotherapy, surgery and into the recovery period.  
The exercise advice given to a treatment-naïve patient will differ from that of a patient during 
active chemotherapy treatment especially in the first days following chemotherapy infusions. In 
the ‘washout period’ after NAC, as the effects of chemotherapy toxicities subside, activity may 
be designed to increase in intensity in preparation for surgery. Nutritional and psychological 
support will likewise adjust to each phase of treatment. In-hospital physiotherapy teams will 
oversee early post-operative recovery, but following discharge, any exercise program clearly 
needs to be sympathetic to the resultant physical deficiencies incurred by the surgery.  
2. Between the time of diagnosis and the beginning of acute treatment 
The timing of introducing prehabilitation programs poses a significant challenge with regards to 
imposed ‘time-to-treat’ treatment pathways. Once staging has been completed, patients may be 
required to attend the hospital multiple times for additional investigations including renal and 
cardiac function, and nutritional optimization prior to starting neo-adjuvant chemotherapy. 
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Patients also take time to process the diagnosis of cancer and the impact it will have on their lives 
and that of their families (Edwards and Clarke, 2004). Initiating exercise training during this 
period is challenging. Opportunities for exercise training need to be accessible and preferably 
provided on-site to avoid additional travel for patients (Ferreira et al., 2018). 
Prehabilitation during NAC aims to reduce physical deconditioning, increase pre-operative 
activity levels and as a result, optimise fitness and improved mental and emotional health ahead 
of demanding surgery. Much of the reported research in exercise training has focused on the 2 – 
6 weeks before surgery. In Figure 2, Jack et al. present the CPEX results of VO2peak before and 
after NAC showing decline of physical function in patients during treatment (Jack et al., 2014). 
This study highlights that exercise interventions, in patients undergoing neo-adjuvant 
treatments, need to be introduced from the time of diagnosis rather than waiting to begin 
prehabilitation in the pre-surgery period.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 A ladder plot of oxygen uptake at estimated lactate threshold pre-and-post-
neoadjuvant chemotherapy (NAC) (Jack et al., 2014)  
Printed with permission Copyright © 2014 Elsevier Ltd. All rights reserved 
3. Physical and psychological assessments that establish a baseline function level. 
There is general consensus (Julie K. Silver and Baima, 2013b; Tew et al., 2018) that patients 
undergoing prehabilitation in cancer should undergo baseline assessment of physical and 
psychological function. Cancer treatment is physically, emotionally and psychologically stressful 
(Hellstadius et al., 2016, 2017) . Each patient will have unique comorbidities and physical 
Copyright material removed for thesis 
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capabilities. As a result, physical training needs to be individualized to those specific needs, 
measured against a baseline assessment and with subsequent monitoring and guidance during 
training (Tew et al., 2018) . 
In clinical trials, baseline assessments vary and may include: 6-minute walk test, muscle 
function/strength tests (i.e. leg press and chest press), VO2max as measured by Cardiopulmonary 
Exercise Test (CPEX) or estimated from a sub-maximal test, grip strength, Forced Expiratory 
Volumes (FEV), in addition to measures of insulin resistance, haemoglobin, white cell and blood 
albumin levels.  
Cardiopulmonary exercise testing (CPEX) is a holistic measure of cardiorespiratory capacity and 
oxygen delivery within an individual, including that of skeletal muscle function (Albouaini et al., 
2007). It is a useful tool in risk stratifying patients, may predict post-operative morbidity and can 
guide exercise prehabilitation programs (Levett and Grocott, 2015b). Early mobilization of 
patients is a key aspect of ERAS programs for good reason, given that the pulmonary and systemic 
circulation, and peripheral muscle function are all activated through ambulation of patients post-
operatively. 
 Some of the ‘softer’ physical measures, for example, 6MWT, grip strength and Forced Expiration 
Volume (FEV) used in studies are restricted in how they measure overall physical function. 
However, these limitations need to be weighed against advantages such as ease of access, cost 
and time taken to perform the test.  
Validated psychological and well-being measures are readily available for use in cancer patients 
(EORTC | European Organisation for Research and Treatment of Cancer : EORTC, no date; 
Zigmond and Snaith, 1983; Tennant et al., 2007). Baseline measures will serve to inform the 
clinical team of a patient’s current status, may highlight important areas where intervention may 
be required and also provide valuable context during the survivorship period. 
4. Identifies impairments 
Whilst surgery is still considered to be the cornerstone of curative treatment, discussion with the 
patient involves identifying limiting factors prior to treatment selection. Pre-existing 
comorbidities and specific cancer-related risk factors need to be considered in relation to the 
toxicities resulting from chemotherapy and chemo-radiation treatments. Renal, cardiac and 
pulmonary function, in addition to smoking status, synchronous cancers, morbid obesity and 
mental health are all considerable risk factors for patients. The need for single lung ventilation 
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during oesophagectomy needs to be considered at the outset in relation to patient fitness for 
surgery. 
The Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG Performance Status 
- ECOG-ACRIN, no date) is a standard used by oncologists to establish how the patient’s disease 
affects their daily living abilities and to determine appropriate treatment. Furthermore, personal 
goals and patient wishes should be considered. An understanding of the benefits of physical 
exercise will have a significant influence on the patient’s compliance when enrolling in exercise 
programs. The concept of “teachable moments” where patients are receptive to, and may act 
upon, health advice is particularly relevant to prehabilitation. Nadler et al. discuss some of the 
barriers relating to exercise during cancer treatment including, poor knowledge, lack of time and 
safety concerns (Nadler et al., 2017). Advice from oncology care providers may be important in 
addressing these concerns. In addition, tailored exercise programs, targeted to the needs and 
preferences of the patient, combined with the use of group activities including family and friends, 
and regular monitoring with feedback, are some of a number of ways to improve motivation and 
adherence. 
 A number of strategies are emerging to adequately assess elderly and more complex patients 
prior to surgery. These include dedicated, high-risk, anaesthetic clinics and specific services 
overseen by Geriatricians e.g. POPS - ‘Proactive care of older persons undergoing surgery’ 
services. These services assist in identifying modifiable impairments which, if not addressed, 
would pose increased risk of post-operative problems in older, or less fit, surgical patients (Harari 
et al., 2007). Once identified, these impairments may be optimized through prehabilitation.  Carli 
et al. described mitigation of the post-operative stresses of surgery using an integrated multi-
disciplinary approach of prehabilitation in the pre-operative period, highlighting especially the 
benefits in the older patient (Carli and Ferreira, 2018). Of note, physical activity levels and 
physical capacity in the general population falls significantly with age. In the UK population, 43% 
of 55 to 64-year olds are inactive (less than 30 minutes of physical activity per week), rising to 
68% inactive in the 75+ years age group. Accordingly, prehabilitation to improve physical capacity 
is of greater importance in older patients and likely to become increasingly important as activity 
levels in the general population continues to fall (Sport England, no date) 
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5. Provide interventions to promote the physical and psychological health of the patient 
that reduce the incidence and severity of future impairments 
Macmillan Cancer Support (How active should I be? - Information and support - Macmillan Cancer 
Support, no date) encourage the World Health Organisation guideline of Activity in Healthy 
Adults (World Health Organization, 2015). The recommendation is for “150 minutes/week of 
moderate intensity or 75 minutes of high intensity activity. Adults (aged 19 – 65+) should also 
aim to undertake activity to improve muscle strength and balance training sessions twice per 
week”. The advice for patients with cancer is to aim to achieve the WHO guidelines but to adjust 
activity according to their physical symptoms and treatment status (How active should I be? - 
Information and support - Macmillan Cancer Support, no date).  
In a study of physical activity guideline compliance in U.S. adults, Tucker et al.(Tucker, Welk and 
Beyler, 2011) reported that fewer than 9.6% met the WHO guideline for physical activity when 
objectively monitored on accelerometer. In contrast, the self-reported level of compliance was 
63%.  In a Sport and Physical Activity: Special Eurobarometer Report (2013), 29% of EU adults 
claimed to undertake vigorous activity for 1-3 days per week. 25% of adults reported participating 
in moderate activity, 4-7 days per week (‘Special Eurobarometer 412 SPORT AND PHYSICAL 
ACTIVITY REPORT Special Eurobarometer 412 / Wave EB80.2-TNS Opinion &amp; Social’, no 
date). 
Physical training interventions in past studies described a range of exercises for pre-operative 
optimization. Some suggested exercise of selected muscle groups to reduce post-op 
complications e.g. Inspiratory Muscle Training, to selectively attempt to reduce post-operative 
pneumonia (Daniela S. Dettling et al., 2013; Banugo and Amoako, 2017; Boden et al., 2018). The 
majority of current trials include a combination of aerobic and resistance training programs. 
(Table1). A meta-analysis by Marzolini et al. reported improved body composition, strength and 
cardiovascular fitness, and ‘probably quality of life as well’, in combined aerobic and resistance 
training versus resistance training alone(Marzolini, Oh and Brooks, 2012). Furthermore, they 
concluded that in stroke patients, aerobic training may be reduced by up to 40%, but with similar 
improvements in mobility and VO2peak, if combined with resistance training (Marzolini et al., 
2018). 
Psychological health of the patient is also important in cancer prehabilitation. The advantageous 
outcomes of exercise on psychological health during cancer rehabilitation have been reported by 
Smith et al. and Losito et al. (Losito, Murphy and Thomas, 2006; Smith, Broomhall and Crecelius, 
2016) These include improved quality of life and cancer-related fatigue. ‘Living with and beyond 
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cancer’ and ‘survivorship’ are terms frequently being used in post-treatment cancer patient 
groups. Physical exercise before, during and after cancer treatment improves physical status and 
quality of life (Losito, Murphy and Thomas, 2006; Lynch, van Roekel and Vallance, 2016; Ubago-
Guisado et al., 2019).  
 
Prehabilitation, cancer and immunity  
The effect of exercise prehabilitation in cancer may also impact on tumour control through 
immune system regulation. In a review of patients who undertook monitored exercise following 
a diagnosis of cancer, there was a lower relative risk of cancer recurrence and cancer-related 
mortality compared to patients who did little or no exercise. Furthermore, the same patients 
experienced fewer or less severe treatment side effects (Cormie et al., 2017). Patients who 
experience complications after surgery have higher rates of cancer recurrence independent of 
tumour stage (Shimada et al., 2017). This implies an immunological component to cancer 
recurrence. Terra et al. (Terra et al., 2012) described inherent activation of  the immune response 
cascade through exercise, eliciting a pro-inflammatory response during moderate intensity 
exercise. However, during high intensity exercise an anti-inflammatory response was noted. 
Hojman (Hojman, 2017a) further described the effects of exercise on the control of immune cell 
function, modulation of inflammatory signalling and regulation of systemic inflammation linking 
these regulatory effects to lowered tumour incidence and disease progression. Pederson et al. 
linked exercise to reduced tumour growth and through increased infiltration of natural killer (NK) 
cells in exercised mice (Pedersen et al., 2016a). The mechanism of increased mobilization of NK 
cells is speculated to be through increased release of Interleukine-6 (IL-6) myokines in response 
to muscle contraction (Idorn and thor Straten, 2017). Exercise-induced IL-6 is described as having 
a pro-inflammatory effect on bacterial infections and contrasting anti-inflammatory inhibiting 
effect on Tumour Necrosis Factor-alpha (Cullen et al., 2016). Research programs in clinical 
practice aim to provide evidence that exercise reduces the risk of complications and may also 
have immunological benefits on tumour control and recurrent disease. 
 
Summary and clinical implications 
Mortality rates after oesophagectomy have fallen, however morbidity rates remain high. The 
introduction of ERAS programs provided a consolidated framework for improvements of care in 
the peri-operative period and has reduced length of hospital stay. The introduction of 
prehabilitation programs, in order to optimise patients physically and psychologically for surgery, 
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have proved to be beneficial in some tumour groups. The health benefits, safety and biological 
benefits on tumour control following exercise have also shown positive results. A number of 
questions remain in regards to prehabilitation in oesophageal cancer. These include the timing 
and accessibility of the intervention, how to improve compliance, the optimal makeup of training 
programmes, how to measure physical performance and, the cost-effective implementation of 
prehabilitation into standard practice.  
With a coordinated, multidisciplinary approach to introducing a holistic prehabilitation program 
in cancer care, there is realistic potential to change the current status quo and improve surgical 
outcomes, physical health, psychological well-being and long-term survival in these patients.  
 
Conclusion 
‘Living with and beyond cancer’ begins at the time of cancer diagnosis - so too should 
prehabilitation. Dr Nick Cavill, a health promotion consultant said: “If exercise were a pill, it would 
be one of the most cost-effective drugs ever invented”. Therefore, the challenge to those making 
clinical decisions in cancer care is to develop a greater understanding of exercise prehabilitation 
and its active promotion as an integral part of the treatment pathway. Much is said about 
empowering patients with long-term conditions and joint clinical decision-making with patients. 
ERAS provided an excellent matrix for a coordinated, multi-disciplinary approach to peri-
operative improvements in patient care. Prehabilitation, or ‘Pre-ERAS’, is the opportunity to 
broaden the benefits of ERAS to include engagement of the patient in their care from the time of 
diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Future research agenda 
• To define the timing and accessibility of the exercise prehabilitation 
intervention in order to optimise compliance 
• To identify the optimal structure of the exercise program during the treatment 
pathway 
• To achieve consensus on how best to measure baseline function and monitor 
physical performance changes during prehabilitation.  
Practice Points 
• Exercise during cancer treatment is safe and advisable 
• Prehabilitation in cancer should commence at diagnosis 
• Benefits of prehabilitation extend beyond physical optimisation and include 
general health, well-being, psychological improvements and immune function 
support 
• Prehabilitation should form the starting point of Enhanced Recovery After 
Surgery Programs 
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See following page for:  
Table of Registered Clinical Prehabilitation Trials 
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Part B 
Chapter 4 The Pre-EMPT trial 
 
4.1 Protocol 
The study protocol was designed to dovetail with the standard peri-operative pathway for 
patients with operable, oesophageal adenocarcinoma. 
 Current best practice treatment for patients diagnosed with operable oesophageal 
adenocarcinoma includes 8-9 weeks of pre-operative, or neo-adjuvant, chemotherapy followed 
by surgery. The currently recommended period between completing NAC and undergoing 
surgery is approximately 6 weeks after completing the last cycle of NAC. Depending on the post-
operative histopathological tumour and lymph node result, patients may be advised by the MDM 
to undergo further post-operative, or adjuvant, chemotherapy or chemo-radiotherapy. Adjuvant 
treatment commences after the patient has been reviewed by the surgical team and have been 
assessed as fit to commence further oncological treatment. The oncology team subsequently 
review the patient for fitness to commence treatment before recommending adjuvant treatment 
starting. 
 
The Pre-EMPT trial assessments, intervention and data collection took place at Baseline (after 
confirmed diagnosis with MDM treatment recommendation but prior to starting treatment), 
within a week after completing NAC (Post-NAC), within 1 week before surgery (Pre-surgery) and 
before commencing adjuvant oncological treatment – if recommended.  
 
Figure 4-1 represents the time-line of patient pathway, associated trial activities and data 
collection points of patients, during the treatment pathway that consented to participate in the 
trial. 
 
 
 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Flowchart of Pre-EMPT trial activity  
  
Diagnosis, MDM 
treatment plan, 
Consent to study 
participation
•Baseline 
CPEX, study 
bloods, HRQL, 
data 
collection
Neo-adjuvant 
chemotherapy 
•Post-NAC 
CPEX, study 
bloods, HRQL, 
data 
collection
Surgery
•Pre-surgery 
CPEX, study 
bloods, HRQL, 
data 
collection
Day 1 
post-op
•Bloods
Day 3 
post-op
•Bloods
Day 6 
post-op
•Bloods
Post-operative discharge followed by post-operative out-patient clinical review 
Post-surgery/pre-
adjuvant 
treatment
•Post-surgery 
CPEX, study 
bloods, HRQL, 
data 
collection
6 months post-
op
•HRQL, data
12 months post-
op
•HRQL, data
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4.2  Trial participation – identifying, approaching and consenting patients 
Patients were identified in the UGI MDM and followed up in the joint surgical-oncology clinic 
following an initial discussion with a clinician (surgeon, oncologist, physiotherapist or specialist 
nurse). Standard guideline of Good Clinical Practice (Good Clinical Practice - Health Research 
Authority, no date) were followed at all times.  
Patients had a face-to-face consultation with the research coordinator or research nurse during 
which an explanation of information was provided verbally. A Patient Information Leaflet was 
also given to the patients to take away to read. They were given 24 hours to consider 
participation in the trial before consenting and starting any trial-related activity.  
In some cases, patients who had short breach dates (dates by which time they had to commence 
treatment according to NHS guidelines) were unable to participate in the trial due to baseline 
measures being required in a small ‘window of opportunity’. In practice, such limitations would 
not necessarily exist, and more patients would be able to participate in an exercise 
prehabilitation program if it were offered at the treatment centre. This would be a significant 
benefit of the structured exercise program being available, supervised and supported onsite. 
 
4.3 Exercise Intervention 
It is readily accepted that exercise is beneficial to the general health of populations. The benefits 
are widely published in specific disease-types. Stress, both physical and psychological, have also 
shown to activate signalling pathways in cancer and is associated with the onset or exacerbation 
of diseases (Moreno-Smith, Lutgendorf and Sood, 2010).  
While exercise has been shown to inhibit tumour growth (Pedersen et al., 2016b) it was 
important that any exercise program did not cause patients, on neo-adjuvant chemotherapy and 
already immunocompromised, to become stressed physiologically or psychologically. 
The World Health Organisation (WHO) Guidelines on Physical Activity and Adults (World Health 
Organization, 2015) and Macmillan guidelines for physical activity in patients with cancer 
(Physical activity and cancer - A concise evidence review, 2017) concur in their recommendations 
on physical activity for the adult population whether diagnosed with cancer or not. The WHO 
guidelines are as follows: 
1. “Adults aged 18–64 should do at least 150 minutes of moderate-intensity aerobic physical 
activity throughout the week or do at least 75 minutes of vigorous-intensity aerobic 
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physical activity throughout the week or an equivalent combination of moderate- and 
vigorous-intensity activity. 
2. Aerobic activity should be performed in bouts of at least 10 minutes duration. 
3. For additional health benefits, adults should increase their moderate-intensity aerobic 
physical activity to 300 minutes per week or engage in 150 minutes of vigorous-intensity 
aerobic physical activity per week, or an equivalent combination of moderate- and 
vigorous-intensity activity. 
4. Muscle-strengthening activities should be done involving major muscle groups on 2 or 
more days a week.” (https://www.who.int/dietphysicalactivity/factsheet_adults/en) 
 
In a questionnaire-based Health Survey of Physical activity in adults in England in 2016, nearly 
two-thirds of all adults over the age of 16 reportedly met the WHO guidelines of aerobic activity 
(Health Survey for England 2016 Physical activity in adults Health Survey for England 2016: 
Physical activity in adults, 2017). In the USA, there was a big difference in self-reported versus 
accelerometer-measured compliance with activity guidelines – 62.0% versus 9.6% respectively. 
 
The purpose of the Pre-EMPT program was not to train patients into becoming competitive 
athletes but to improve levels of physical activity according to recommended and approved 
practice. Taking all the above into consideration and working in consultation with the highly 
experienced clinical, physiotherapy and dietetic teams at GSTT, a structured exercise program 
was devised by Professor Whyte and the team at CHHP, based on the WHO and Macmillan 
guidelines for activity in adults and those with cancer.  
The outline of the exercise program with instructions and diagrams is attached (see Appendix A). 
 
4.4 Trial outcome measures 
4.4.1 Clinical outcomes 
Routine data collection of patient demographics, clinical history, tumour characteristics, 
treatment specific details and outcomes were part of routine data collection at St Thomas’ 
Hospital. Additional specific data collected, and analysis is discussed in Chapter 6. 
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4.4.2 CPEX  
CPEX and training took place at CHHP for the Intervention group while the Control group 
undertook their CPEX with Dr Browning at MTWH. 
Other study-related activity was undertaken at the hospital at which the patient was receiving 
treatment. Further CPEX study methods will be described in Chapter 7. 
 
4.4.3 Body composition - Computerised Tomography (CT) body tissue segmentation analysis 
As this was a feasibility and explorative trial, we sought to use various measures to assess the 
outcomes of comparison between the two patient groups. As part of the standard treatment 
pathway CT scans were performed on the thorax and abdomen as part of routine diagnostic at 
baseline. Following NAC, patients underwent a second ‘response to treatment’ scan. Our group 
has previously published on assessment of sarcopenia and muscle deterioration after NAC using 
this method (Yip et al., 2014a).  
Body composition (fat and muscle segmentation) was assessed using axial images processed from 
the scans using ‘FATS’ software developed in at King’s College London (KCL). See Chapter 8 for 
details and outcomes. 
 
4.4.4 Immunity and Inflammatory blood markers 
Exercise has been shown to produce pro-inflammatory and anti-inflammatory responses (Cullen 
et al., 2016) and immune function regulation (Hojman, 2017b). The blood markers selected for 
this trial were based on markers from studies in elite athletes undergoing changes in their 
training programs.  
We aimed to establish a baseline measure of immunity and inflammatory markers in patients 
diagnosed with oesophageal adenocarcinoma. In addition, we aimed to assess the changes in 
these markers between patients undertaking a structured exercise program and those who 
followed a standard treatment pathway. There were, at the time of study design, no published 
reports of these blood markers in oesophageal cancer. 
Study-specific bloods samples were taken at 7 time points in the study:  
Baseline; Post-NAC; Pre-surgery; Day 1 post-op; Day 3 post-op; Day 6 post-op; and Pre-adjuvant 
treatment. Chapter 9 details the method of blood marker analysis. 
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4.4.5 Health-Related Quality of Life 
Health Related Quality of Life (HRQL) in patients undergoing oncological and surgical treatments 
for oesophageal cancer is historically poor with prolonged physical and psychological return to 
full function. The aim of this study was to assess the differences, if any, of structured exercise 
during treatment. Validated questionnaires were employed to assess patient-reported outcome 
measures (PROMS). Two questionnaires were used to assess physical symptoms of quality of life, 
and mental health and wellbeing. 
The European Organisation for Research and Treatment of Cancer (EORTC) enable the use of 
validated general and disease-specific questionnaires to assess the quality of life of cancer 
patients. We used the general assessment EORTC QLQ-30 and disease specific EORTC QLQ-OES18 
modules (EORTC | European Organisation for Research and Treatment of Cancer : EORTC, no 
date). 
The Short Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS) uses 7 of the 14 statements 
from the longer Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). The statements scored 
are worded from a positive perspective and are not cancer specific (Stewart-Brown et al., 2009). 
Chapter 10 deals with Quality of Life in more detail.  
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Chapter 5 Trial Participation 
 
5.1 Background 
5.1.1 Identifying, approaching and enrolling patients 
In both Interventional and Control groups, patients were identified through the UGI MDM. 
Following an initial clinical consultation in the surgical-oncology clinic, patients were approached 
for a trial discussion by the relevant research coordinator or research nurse. 
In each of the groups there were eligible patients who were suitable for trial participation but 
were unable to start baseline trial activity due to imminent ‘breach dates’ to commence cancer 
treatment. (In the UK, NHS hospitals may be fined if a patient commences treatment more than 
62 days after initial cancer diagnosis). These patients were excluded from the trial and analysis. 
Patients in the Control cohort were asked to agree to undertake all the specific trial activity at 
each time point but were informed that there was no anticipated direct benefit to them. As part 
of the standard care for patients undergoing UGI cancer surgery at St Thomas’, patients were 
informed of the Macmillan recommended activity guidelines and the Enhanced Recovery after 
Surgery (ERAS) protocol in which they would be included.  
Patients in the Interventional cohort were invited to agree to undertake all the specific study 
activity with the addition of a structured exercise program delivered to them at the Centre for 
Health and Human Performance (CHHP) by a Specialist Exercise Physiologist. Patients were 
encouraged to attend training sessions at CHHP but also given advice on following the structured 
exercise program at home during their cancer treatment. In this group, training was also offered 
when attending for a CPEX.  
According to ethical approvals, all patients were informed that trial participation was entirely 
voluntary and that they were at liberty to withdraw from the study at any point. 
 
5.2 Aim 
The aim of this study was to assess the feasibility of patients, recently diagnosed with operable 
oesophageal adenocarcinoma, undertaking a structured exercise program during neo-adjuvant 
chemotherapy and prior to surgery. The outcomes of measured physiological, physical and 
mental changes during the course of the study would assist in determining the feasibility of 
implementing such an exercise program in treatment pathways. 
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5.3 Results 
At time of writing, participation numbers in the two groups provided a good comparative basis 
for this interim analysis. See Figures 5-1 and 5-2: 
35 vs 34 patients had been approached in the Control and Intervention groups respectively.  
Prior to Consent, 7 vs 3 patients were deemed ineligible following further investigations or 
became ineligible due to a change in treatment pathway. Eleven patients in each group declined 
participation. Some of the reasons for non-participation in both groups were: 
• Patients feeling that they ‘had enough going on already’ and did not wish to add to their 
current burden 
• Additional hospital visits relating to the pending treatment 
• Additional visits for study activity 
• Distance to travel for additional study visits 
In the Intervention group, some further reasons for non-participation were: 
• ‘I’ll do exercise on my own’ / ‘I do enough exercise already’ 
• I would do exercise if it were provided at the out-patient clinics 
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Figure 5-1 Flowchart of participation: Control group 
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Figure 5-2 Flowchart of participation: Intervention group 
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17 Control vs 20 Intervention patients gave written informed consent to trial participation. 3 
patients in each group withdrew or were withdrawn from the trial for medical reasons unrelated 
to their ability to participate in exercise. As a result, 14 and 13 patients were in the Intervention 
and Control group, respectively. One patient in each cohort did not proceed to surgery following 
NAC. The remaining patients all proceeded to surgery, leaving 13 vs 12 patients for analysis after 
surgery in the Control versus Intervention groups. 
Written feedback received from the Intervention participants at the end of the trial was positive 
and encouraging of others to participate in a similar program. This is discussed further in Chapter 
10.4. 
Demographic and clinical analysis of trial recruits in the Control group indicated that non-
participants were slightly older (67.0 vs. 63.6 years) and had fewer numbers of comorbidities 
than participants, especially hypertension (see Table 5-1). Body Mass Index (BMI) was similar, as 
was smoking status. The distance patients would have been required to travel for study 
participation was not recorded. 
In the Intervention group, analysis of demographics and clinical characteristics in non-
participants and patients who withdrew from active participation (did not undergo adequate 
study measures of at least 2 CPEX’s before surgery), was also carried out (see Table5-2).  
Patients who declined participation or who withdrew from active participation had higher BMI’s 
compared to study participants (Declined - 29.7 kg.m-2 vs. Withdrew - 29.1 kg.m-2 vs Participants 
- 24.7 kg.m-2). Furthermore, participants who withdrew were younger than either those that 
declined participation or active study participants (Declined - 65.0 vs. Withdrew - 58.7 vs. 
Participants - 63.0 years respectively). 
In the Control group, trial participants had a greater number of cumulative comorbidities 
compared to either those patients who declined participation or who withdrew from active 
participation in the Intervention group. Smoking status was similar between Interventional 
participants and those who withdrew.  
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Table 5-1 Demographic and clinical characteristics of Control group by participation status 
Baseline characteristics Control group     
  Number 
declined  
 (%) Number 
included 
 (%) p- value 
Total  11 
 
14 
 
  
Missing information  2 
 
0 
 
  
Age-median years 67 
 
63.6 
 
0.46 
BMI (kg.m-2) (median) 28.8 
 
28.6 
 
0.95 
Sex 
    
  
Male 8 (89) 13 (93) 0.74 
Female 1 (11) 1 (7)   
Tumour location 
    
  
Lower oesophagus, Siewert type 1 6 (66) 8 (57) 0.63 
Siewert type 2 1 (11) 6 (43)   
Siewert type 3 3 (33) 0 (0)   
Clinical stage – TNM 7&8 
    
  
cT1 0 (0) 0 (0) 0.3 
2 0 (22) 1 (7)   
3 7 (78) 13 (93)   
4 0 (0) 0 (0)   
cN0 1 (11) 1 (7) 0.78 
1 6 (67) 8 (57)   
2 2 (22) 5 (36)   
3 0 (0) 0 (0)   
cM0 9 (100) 14 (100)   
Comorbidities (NOGCA) 
    
  
None 2 (22) 1 (7) 0.11 
1-Cardiovascular disease 5 (56) 10 (71) 0.44 
2-COPD, Asthma 0 (0) 4 (28) 0.08 
3-Chronic renal impairment 0 (0) 1 (7) 0.41 
4-Liver failure/cirrhosis 0 (0) 0 (0)   
5-Diabetes 1 (11) 0 (0) 0.2 
6-Mental illness (requiring 
medication) 
0 (0) 0 (0)   
7-Cerebro/peripheral vascular 
disease 
0 (0) 0 (0)   
8-Barrett’s 0 (0) 1 (7) 0.41 
9-Other significant disease 6 (67) 8 (57) 0.65 
Smoking status 
    
  
Ex-smoker 3 (33) 7 (50) 0.53 
Non-smoker/never 3 (33) 5 (36)   
Smoker  3 (33) 2 (14)   
NAC Type 
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FLOT n/a 
 
4 (29)   
Other  n/a   10 (71)   
 
 
Table 5-2 Demographic and clinical characteristics of Intervention group - by participation 
status. 
Baseline characteristics Intervention group 
  
p- 
value 
  
Number 
declined  
(%) 
Number 
withdrew  
(%) 
Number 
included  
(%) 
  
Total  11  7  13    
Age-median years 65  58.7  63  0.43 
BMI (kg.m-2) (median) 29.7  29.1  24.7  0.08 
Sex         
Male 9 (82) 6 (86) 12 (92) 0.38 
Female 2 (18) 1 (14) 1 (8)   
Cancer site         
Lower oesophagus, Siewert 
type 1 6 (55) 3 (43) 5 (38) 0.77 
Siewert type 2 4 (36) 4 (57) 8 (62)   
Siewert type 3 1 (10) 0 (0) 0 (0)   
Clinical stage         
cT1 0 (0) 0 (0) 0 (0) 0.33 
2 0 (0) 0 (0) 2 (15)   
3 11 (100) 7 (100) 10 (77)   
4 0  0  1 (8)   
cN0 2 (18) 3 (43) 1 (8) 0.45 
1 7 (64) 2 (29) 7 (54)   
2 2 (18) 2 (29) 4 (31)   
3 0 (0) 0 (0) 1 (8)   
cM0 11 (100) 7 (100) 13 (100) - 
Comorbidities (NOGCA)         
None 3 (30) 0 (0) 2 (15) 0.26* 
1-Cardiovascular disease 6 (60) 4 (57) 7 (54)   
2-COPD, Asthma 0 (0) 2 (29) 2 (15)   
3-Chronic renal impairment 
1 (10) 1 (14) 1 (8)   
4-Liver failure/cirrhosis 0 (0) 0 (0) 0 (0)   
5-Diabetes 0 (0) 1 (14) 3 (23)   
6-Mental illness (requiring 
medication) 0 (0) 1 (14) 1 (8)   
7-Cerebro/peripheral 
vascular disease 1 (10) 0 (0) 1 (8)   
8-Barrett’s 0 (0) 0 (0) 0 (0)   
9-Other significant 
condition 3 (30) 4 (47) 7 (54)   
Smoking status         
Ex-smoker 5 (50) 1 (14) 5 (38) 0.15 
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Non-smoker/never 4 (40) 1 (14) 3 (15)   
Smoker  1 (10) 5 (71) 5 (38)   
NAC Type         
FLOT  n/a 3 (43) 4 (31)   
Other   n/a 2 (29) 9 (69)   
missing   n/a 2 (29) 0 (0)   
*p-value from ANOVA (comparison of means) or chi2 (comparison of proportions) 
 
Analysis of fitness levels of participants who withdrew from the study following consent 
demonstrated that participants in both Control and Intervention cohorts had better overall 
fitness (AT and VO2peak) compared with patients who withdrew from participation. (See Table 5-
3) 
 
Table 5-3 Baseline fitness by participation status. 
Baseline 
measures  
Control group Intervention group 
  Withdrew  Participant  Withdrew  Participant  
  n=3 (%) n=14 (%) n=7 (%) n=13 (%) 
Mean (SD)           
Median (IQR)           
            
Anaerobic 13.5 (1.0) 15.2 (3.6) 14.3 (2.8) 17.6 (3.3) 
p=0.11 12.9 (12.9-14.7) 14.2 (13.1 - 17.0) 14.7 (12.2 - 16.5) 17.9 (16.9 - 20.9) 
            
VO2peak 20.5 (2.8) 23.4 (4.1) 22.6 (1.5) 27.6 (5.6) 
P=0.04 20.4 (17.7-23.3) 22.5 (19.6 - 26.3) 22.4 (21.5 - 23.8) 27.6 (26.5 - 31.1) 
            
VeVCO2 30.7 (2.1) 29.8 (3.1) 31.6 (4.9) 31.1 (4.0) 
p=0.75 30 (29.0-33.0) 30 (28.0 - 31.0) 33 (28.4 - 34.8) 30.3 (27.8 - 32.4) 
            
BMI 30.6 (3.1) 28.6 (7.4) 30.1 (3.8) 25.5 (4.9) 
p=0.27 31.6 (27.1-33.0) 28.4 (23.1 - 30.7) 28.7 (27.1 - 34.7) 24.7 (21.5 - 27.9) 
*p-value from ANOVA 
 
After adjusting for age and gender, established lifestyle factors of obesity and smoking, are 
reported to increase risk of developing oesophageal cancer (Veugelers et al., 2006). The Pre-
EMPT trial population was representative of these typical characteristics. Participants in the 
trial had overall more comorbidities, were older but fitter, and less obese, than those who 
declined or withdrew their participation.  
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5.4 Discussion 
The analysis of patients who declined to participate in the trial, and those in the Intervention 
group who only undertook baseline assessments, provided useful insights into potential patient 
selection for introducing prehabilitation as part of routine care pathways. Patients who had 
higher BMI tended to withdraw from or decline to participate in the exercise intervention. In 
addition, participants who withdrew during the study tended to be to have lower fitness levels 
and were also younger. As with all specialist services, it is important to offer the same choice to 
all patients but also to assess which patients are likely to benefit by complying with protocols and 
by assessing which patients will need more encouragement and support to comply with the 
protocols.  
Feedback from Intervention participants was positive and most recommended a structured 
exercise program to others in similar circumstances. 
 
5.5 Conclusions 
Exercise during neo-adjuvant chemotherapy was found to be feasible and viable in patients with 
operable oesophageal adenocarcinoma. Participation and compliance was more sustained in an 
older group of patients and those who had BMIs within the normal weight range. Patients in this 
study who had a higher BMI, and are more likely to be less active, seemed to be more resistant 
to participation in an exercise intervention. This group of patients may need more 
encouragement and support to undertake this type of program.  
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Chapter 6  Clinical Outcomes after Surgery 
 
6.1 Background 
As described previously, oesophagectomy is a high-risk, invasive surgery associated with high 
morbidity. Patient selection for cancer surgery is based largely on the disease location and 
tumour stage of invasion, with fitness of the patient taken into consideration. 
In the UK, the surgical pathway follows defined protocols and the opportunity for patient 
selection according to comorbidities and fitness is very different on a cancer pathway compared 
to that of a benign pathway when expedition of surgery is not within a defined timeframe. The 
window of opportunity for pre-surgical patient optimisation is small and impacted by the 
reduction of fitness and development of new, chemotherapy-associated, comorbidities. 
 
6.2 Aims 
Amongst the broad clinical outcome measures routinely recorded at this institution, we aimed 
to assess the clinical and pathological outcomes of patients undertaking a structured exercise 
prehabilitation program versus patients in a ‘standard care’ control treatment pathway, to 
determine: 
• The impact of exercise prehabilitation on post-operative complications 
• The impact of prehabilitation on overall length of hospital stay post-operatively 
• Onco-pathological outcomes of exercise during chemotherapy on histopathological 
examination outcomes 
• Peri-operative oncological treatment completion rates between the intervention and 
control groups. 
 
6.3 Methods 
Following consent to trial participation, clinical data collection was carried out throughout the 
patient pathway, starting at MDM discussion and identification of potential participants. Clinical 
results were recorded for all patients who consented to participation under ethics approval for 
this trial. For eligible patients who did not consent to the trial, basic demographic data was 
recorded under ethical approval of the Guy’s and St Thomas’ Oesophago-gastric Database: REC. 
17/NW/0377, for the purpose of assessing patient participation within the context of feasibility. 
Data was sourced from Electronic Patients Records (EPR), Cancer Information System 
(CIS/MOSAIQ), face-to-face patient discussion, in consultation with Consultant Clinicians and 
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feedback from questionnaires. 
 
6.4 Results 
6.4.1 Baseline patient and tumour characteristics 
At baseline, the number of participants, ages and age-range, gender, tumour location and TNM-
stage were comparable across the two groups. There were a greater number of non-smokers in 
the Control group (5 vs. 3), while ‘current smoker’ status was higher in the Intervention group (5 
vs 2). (See Table 6.1) 
There were a higher number of cardiovascular and pulmonary comorbidities in the Control versus 
Intervention groups (14 vs. 9) which, along with a higher BMI (28.3 vs 24.7 kg.m-2) may have 
contributed to the lower recorded baseline fitness of AT and VO2peak in the Control group (see 
Chapter 7.4). 
6.4.2 Oncological and surgical treatment 
Oncological treatment within the two groups was very similar. At the start of the study, peri-
operative treatment with epirubicin, cisplatin and 5 flurouracil (ECF) or epirubicin, oxaliplatin and 
capecitabine (ECX) were considered to be the first choice regimens (Cunningham et al., 2006b). 
Both included 3 cycles of chemotherapy before and after surgery. Following publication of the 
FLOT trial (Al-Batran et al., 2017), oncological practice changed simultaneously to 4 cycles of pre 
and post-operative FLOT. The study protocol accommodated this change. One patient in the 
exercise group underwent additional radiotherapy prior to surgery.  
Oesophagectomy included transhiatal and transthoracic resections at the discretion of the 
individual surgeon, taking into account both patient and tumour characteristics. All patients in 
the Control group underwent trans-thoracic surgery compared to 75% of the patients in the 
Intervention group, 3 of whom underwent transhiatal oesophagectomy. Transhiatal 
oesophagectomy may be performed in patients with oncologically suitable tumours, with the 
perceived benefit of avoiding one-lung ventilation. Of patients who underwent transhiatal 
oesophagectomy, one patient developed a pneumothorax due to displacement of a chest drain. 
A new drain was inserted, and the patient was admitted to the Intensive Care Unit (ICU). Another 
patient suffered incarceration of an existing hernia requiring return to theatre and escalation of 
care. 
 
 
 
58 
 
 
Table 6-1 Clinical Outcomes: Control and Intervention cohorts 
  Control Group   Intervention Group  
p-
value 
Total patients n=14  n=13   
Age – median (IQR) 67.2 (42.5-77.9)   63 (40.0-76.3)   0.73 
Age range (years) 42.5-77.9  40.0-76.3   
 
     
Sex Number % Number %  
Male 13 (93) 12 (92) 0.96 
Female 1 (7) 1 (8)  
      
BMI –baseline (kg.m-2): Median (IQR) 28.3 (23.1-30.8)  24.7 (21.5-27.9)   
Smoking status     
 
Ex-smoker 7 (50) 5 (38) 0.35 
Non-smoker (+never) 5 (36) 3 (24)  
Smoker  2 (14) 5 (38)  
Diagnostic tumour location: 
oesophagus/GOJ (Siewert 1,2,3) 
    
 
Lower 1/3; Siewert type 1 8 (57) 5 (38) 0.33 
Siewert type 2 6 (43) 8 (62)  
Siewert type 3 0 (0) 0 (0)  
Clinical stage at diagnosis – TNM 7 & 8      
T-stage     
 
X 0 (0) 0 (0) 0.95 
1 0 (0) 0 (0)  
2 1 (7) 2 (15)  
3 13 (93) 10 (77)  
4 0 (0) 1 (8)  
N-stage     
 
X 0 (0) 0 (0) 0.74 
0 1 (7) 1 (8)  
1 8 (57) 7 (54)  
2 5 (36) 4 (31)  
3 0 (0) 1 (8)  
M-stage     
 
0 14 (100) 13 (100)  
1 0 (0) 0 (0)  
Comorbidities (NOGCA)      
 
none 1 (7) 2 (15)  
1 – Cardiovascular disease 10 (71) 7 (54)  
2 – COPD, Asthma 4 (29) 2 (15)  
3 – Chronic renal impairment 1 (7) 1 (8)  
4 – Liver failure/ cirrhosis 0 (0) 0 (0)  
5 - Diabetes 0 (0) 3 (23)  
6 – Mental illness (requiring medication) 0 (0) 1 (8)  
7 – Cerebro/peripheral vascular disease 0 (0) 1 (8)  
8 – Barrett’s oesophagus 1 (7) 0 (0)  
9 – Other significant condition 8 (57) 7 (54)  
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Six patients in each group, 46% Control and 50% Intervention, experienced no post-operative 
complications. Four patients in each group (36% and 33% respectively) required a pharmaceutical 
intervention only. The remaining 3 patients in the Control group, and 2 in the Intervention group, 
required surgical or radiological intervention. Whether the surgical intervention and ITU 
admission were related to a patient fitness, is debatable. 
Post-op complications recorded using the NOGCA and ECCG sub-headings did not provide any 
specific insights due to large numbers of complication categories versus the small numbers of 
patients in this interim analysis. 
Overall, the median hospital length of stay was shorter in the Control group, 9 days (range 7–44 
days, IQR 8-12 days) versus 10.5 days (range 9-17 days, IQR 9-13 days). This is assumed to be due 
to the non-cancer related surgical ‘return to theatre’ and Intensive Care Unit admissions in the 
exercise Intervention group. 
(See Table 6.2) 
There were no in-hospital, 30-day or 90-day deaths post-surgery in either group. 
 
Table 6-2 Oncological and Surgical outcomes  
  Control   Intervention  p-value 
Total patients n=14 % n=13 %  
NAC regimen       
ECX 8 (57) 7 (54) 0.99 
FLOT 4 (29) 4 (31)  
Other 2 (14) 2 (15)  
NAC completed as scheduled      
Yes  12 (86) 9 (69) 0.45 
Dose reduced 2 (14) 3 (23)  
Delayed  0 (0) 1 (8)  
Did not proceed to surgery 1 (7) 1 (8)  
      
Number proceeding to Surgery n=13  n=12   
Operative approach      
Transthoracic oesophagectomy 13 (100) 9 (75) 0.06 
Transhiatal oesophagectomy 0 (0) 3 (25)  
Operative access      
Open 1 (8) 3 (25) 0.24 
Laparoscopically assisted abdomen, 
completed 
12 (92) 9 (75)  
Lap to open 0 (0) 0 (0)  
Post-op complications:      
Clavien-Dindo      
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none 6 (46) 6 (50) 0.29 
1,2 4 (36) 4 (33)  
3a 3 (23) 0 (0)  
3b 0 (0) 1 (8)  
4 0 (0) 1 (8)  
NOGCA      
0 - none 6 (46) 6 (50)  
1 - Pneumonia 0 (0) 4 (33)  
2 - ARDS 0 (0) 1 (8)  
3 - PE 0 (0) 0 (0)  
4 – Pleural effusion 0 (0) 0 (0)  
5 – Anastomotic Leak 2 (15) 0 (0)  
6 – Chyle leak 0 (0) 0 (0)  
7 – Haemorrhage 0 (0) 0 (0)  
8 – Cardiac complication 1 (8) 1 (8)  
9 – Acute renal failure 0 (0) 0 (0)  
10 – Wound infection 0 (0) 0 (0)  
98 - Other 2 (23) 2 (17)  
ECCG      
P - Pulmonary 4 (31) 4 (33)  
C – Cardiac 3 (23) 1 (8)  
G – Gastrointestinal 2 (15) 0 (0)  
U – Urologic 1 8 0 (0)  
I – Infection 0 0 0 (0)  
N/P – Neurologic/ 2 15 1 (8)  
Psychiatric      
T - Thromboembolic 1 (8) 0 (0)  
W/D – Wound/Diaphragm 0       (0) 0 (0)  
O – Other 1 (8) 2 (17)  
E- Escalation of care 0 (0) 1 (8)  
ITU admission 
    
 
Yes  0 (0) 2 (17) 0.13 
No  13 (100) 10 (83)  
       
Total days in OIR/HDU Median (IQR) days 2 (2-5)  3 (2-4) 
 
 
Overall length of Hospital stay (from date of 
surgery) Median (IQR)days 
9 (8-12)  10.5 (9-13)   0.17 
In-hospital mortality      
Yes 0 (0) 0 (0)  
No 13 (100) 12 (100)  
30-day mortality      
Yes 0 (0) 0 (0)  
No 13 (100) 12 (100)  
90-day mortality      
Yes 0 (0) 0 (0)  
No 13 (100) 12 (100)  
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6.4.3 Histopathological Outcomes 
Of particular note are differences between the Control and Intervention group 
histopathologically-assessed tumour responses to chemotherapy. 
As standard at the centre, histopathology reports included the Mandard Tumour Regression 
Grade (MTRG) (Mandard et al., 1994) which was developed as an objective measure for 
evaluation of tumour regression following chemoradiotherapy for oesophageal carcinoma. 
Histopathological assessment identifies microscopic regressive cellular and stromal changes in 
the resected tumour tissue. In the UK, it is the most widely used histopathological measure of 
cancer regression and response to chemotherapy in oesophageal adenocarcinoma and has been 
recommended for use in histopathological reporting of gastrointestinal cancers treated with neo-
adjuvant therapies (Thies and Langer, 2013).  
 
 
 
 
 
 
 
 
 
Figure 6-1 Mandard Tumour Regression Grade 
 
In this cohort-controlled group of patients, histopathological examination of resected tumours in 
patients in the Intervention group, revealed that 45.4% had ‘no or rare residual cancer cells’ 
following chemotherapy, with a MTRG of 1 or 2 (n=5) compared to 0% (n=0) in the Control group. 
An MTRG score of 3, showing greater evidence of fibrosis to residual cancer cells, was observed 
in 27.3% (n=3) and 30.8% (n=4) in the prehabiliation versus Control cohorts. Likewise, poor or no 
regression measures of MTRG 4 and 5 were 27.3% (n=3) versus 69.2% (n=9) respectively. For the 
MTRG analysis, one patient was excluded as they had additional radiotherapy. 
Mandard Tumour 
Regression Grades 
 
1 No residual cancer cells 
2 Rare residual cancer cells 
3 Fibrosis outgrowing residual cancer cells 
4 Residual cancer cells outgrowing fibrosis 
5 Absence of regressive changes 
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Figure 6-2 Graph showing histopathological Mandard Tumour Regression Grade 
 
Tumour ‘downstaging’ following chemotherapy has been shown to be associated with 
improved survival in resectable oesophageal adenocarcinoma (Andrew R. Davies et al., 2014). 
On comparing clinical and pathological T- stage (Baseline versus post-NAC) in the Control and 
Intervention groups, a greater number of patients’ tumours were down-staged after NAC in the 
Intervention group, 7 vs. 4 patients (See Figure 6-3). 
 
 
Figure 6-3 Histopathological Tumour downstaging 
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Histopathological tumour stage, measured according to the ypTNM post-neoadjuvant therapy 
staging (Thomas W. Rice et al., 2016), showed better outcomes in the patients in the Intervention 
group. T-stage results, indicating depth of tumour invasion were improved: T0-2 – 50% (n=4) vs. 
30.8% (n=1) Intervention vs. Control; T3 – 42% (n=5) vs 62% (n=8) respectively; and T4 – 1 patient 
in each group. 
Similarly, there was greater downstaging of nodal disease in the Intervention group, 8 vs. 6 
patients while pathological N-stage showed upstaging of nodal disease in 6 vs. 2 patients in the 
Control group with (See Figure 6-4). 
Overall, histopathological nodal stage post-operatively was lower in the Intervention vs Control 
groups: N0-1 83.3% vs 53.8% ; N2-3 was reported as 16.7% vs 46.2% respectively.  
Median numbers of lymph nodes resected at surgery and examined were comparative in the two 
groups. 
 
 
Figure 6-4 Histopathological Nodal downstaging 
 
Additional prognostic cancer biological markers were recorded. Tumour differentiation was 
more favourable in the Intervention group with poor cellular differentiation being lower, 50% 
vs 69%; Moderate cellular differentiation was higher in the Intervention versus Controls groups, 
42% vs 31%;  1 patient in the Intervention group resulted in complete cancer regression in the 
resected tumour. 
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Lymphovascular/perineural tumour invasion was more prevalent in the Control group: 42% vs. 
62% (See Table 6-3). 
 
Table 6-3. Histopathological results of resected tumours  
 Control  Intervention  p-value 
Number of surgical  patients n=13 % n=12 %  
Post-op tumour location      
Lower 1/3; Siewert type 1 1 (7) 1 (6) 0.1 
Siewert type 2 4 (28) 5 (29)  
Siewert type 3 9 (64) 11 (65)  
Resection margin status      
R0 10 (77) 8 (67) 0.57 
R1 3 (23) 4 (33)  
Pathological stage – TNM 7&8      
T-stage      
0 0 (0) 1 (8) 0.31 
1 1 (8) 3 (25)  
2 3 (23) 2 (17)  
3 8 (62) 5 (42)  
4 1 (8) 1 (8)  
N-stage      
0 5 (38) 7 (58) 0.34 
1 2 (15) 3 (25)  
2 3 (23) 0 (0)  
3 3 (23) 2 (17)  
M-stage      
0 13 (100) 12 (100)  
1 0 (0) 0 (0)  
       
Post-op differentiation      
CPR 0 (0) 1 (8)  
Well 0 (0) 0 (0)  
Moderate 4 (31) 5 (42)  
Poor 9 (69) 6 (50)  
       
Lymphovascular/perineural invasion      
Yes 8 (62) 5 (42) 0.32 
No 5 (38) 7 (58)  
Signet ring cells      
Yes 4 (31) 3 (25) 0.75 
No 9 (69) 9 (75)  
Mandard Tumour Regression Grade      
1 0 (0) 1 (8) 0.03 
2 0 (0) 4 (33)  
3 4 (31) 4 (33)  
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4 8 (62) 1 (8)  
5 1 (8) 2 (17)  
Total number of lymph nodes examined 
(rounded up) Median (IQR) 
35 (23-44)  29 (27-37)   
 
 
Table 6-4. Cancer recurrence and deaths 
  Control  Intervention  p-value 
Total patients n=13 % n=12 %  
In-hospital mortality      
Yes 0 (0) 0 (0)  
No 13 (100) 12 (100)  
30-day mortality      
Yes 0 (0) 0 (0)  
No 13 (100) 12 (100)  
90-day mortality      
Yes 0 (0) 0 (0)  
No 13 (100) 12 (100)  
12-month mortality 
    
 
Yes 1 (13) 0 (0) 0.30 
No 7 (87) 8 (100)  
<12mth follow-up 5  4   
6mth recurrence-free %(CI) from 
surgery 
 
(100)  (100)  
12mth recurrence-free % (CI) from 
surgery 
 
73 (18-93)  (100) 0.13 
Time to recurrence from surgery 
(mean-months) 
8.3    n/a  
Time to recurrence from diagnosis 
(mean-months) 
13.9    n/a  
12mth Overall Survival from 
surgery* % (CI) 
 
 (83)  (100)  
Time to death from surgery 
(months) 
11.6    N/A  
Time to death from diagnosis 
(months) 
17.6    N/A  
FU time surgery to date last seen 
Median (IQR)-months 
9.6 (6.9-13.6)  15.4 (7.4-20.7)   
Total Follow-up time, diagnosis to 
date last seen Median (IQR)-
months 
14.2 (13.1-18.4)  21.3 (12.5-26)   
Commencement of adjuvant 
treatment  
     
 
Yes 13 (100) 10 (100)  
No 0 (0) 0 (0)  
Not applicable 1  3   
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Time to adjuvant treatment 
Median (IQR)-days 
64 (58-71)  64 (46-74)   
 
 
 
6.4.3 Disease Recurrence and Deaths 
At the time of data analysis, 12-month post-surgery follow-up data was available for 7 of 13 and 
8 of 12 patients in the Control and Intervention groups respectively. During the 12-month follow-
up period, 2 patients in the Control group had confirmed cancer recurrence compared to zero 
patients in the Intervention group.  
There was 1 cancer-related death within 12 months of surgery in the Control group with none in 
the Intervention group. 
Commencement of prescribed adjuvant treatment was similar in both groups of 64 days after 
surgery. 
 
6.5  Discussion 
Tumour response to chemotherapy, with tumour- and lymph-node downstaging are potentially 
the most important prognostic factors in oesophageal cancer. A high proportion of patients 
undergoing oesophagectomy have evidence of micro-metastases at the time of diagnosis and 
surgery. The introduction of NAC has been associated with improvements in survival, cancer 
recurrence and systemic control, however, a large number of patients do not respond to 
chemotherapy. These patients tend to have poorer outcomes. With current protocols of 
neoadjuvant treatment strategies and established methods of pathologically quantifying tumour 
regression, oesophageal cancer is an ideal tumour group on which to examine hypotheses of 
exercise-related oncological benefits. The results from this analysis, showing improvements in 
pathological regression in the primary tumour and lymph nodes and clinical down-staging 
following structured exercise programs are potentially clinically significant and hypothesis 
generating. The results also concur with an increasing body of evidence supporting exercise in 
animal cancer models. 
 
6.6 Conclusions 
This is the first study in patients diagnosed with oesophageal adenocarcinoma, and I believe in 
humans undergoing neo-adjuvant chemotherapy, to suggest that there may be the outcome of 
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improved cancer control both in the resected tumour, lymph nodes and in reduced disease 
progression after surgery. It is an unexpected and clinically important finding which may to be 
applicable to other cancers. 
Further research in collaboration with other specialist centres will be essential in validating these 
notable and clinically relevant trial outcomes. 
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Chapter 7 Cardiopulmonary Exercise Testing (CPEX) 
 
7.1 Introduction and rationale 
In a clinical research context, CPEX testing is a well-recognised, quantitatively measurable, 
validated and objective method for assessing an individual’s fitness or functional capacity. CPEX 
incorporates the functions of the cardiac, circulatory and respiratory systems with the altered 
muscular, metabolic and biochemical system responses when subjected to stress (Melzer, 2011). 
CPEX measures the physiological demands and effects of increased oxygen requirements 
associated with increased exercise intensity (Sue et al., 1988), providing useful comparative 
information with the oxygen demands during surgery and the post-operative period (Older and 
Smith, 1988). This was of relevance in our cohort of study participants who were on a peri-
operative treatment pathway, with NAC deconditioning prior to surgery.  
Furthermore, CPEX is an objective measure to assess severity and impact of underlying 
impairments, such as comorbidities, rather than evaluating the cause thereof. It is, therefore, an 
appropriate measure for baseline fitness and subsequent deconditioning in patients undergoing 
treatment for cancer that may induce comorbidities as a result of drug therapy and associated 
toxicities. 
 
7.2 Aim 
To examine fitness changes in patients undertaking a structured exercise program during NAC 
and in preparation of surgery compared to those on a standard pathway. 
 
7.3 Methods 
CPEX testing was undertaken at two centres. Testing in the Control cohort was performed by a 
Consultant Anaesthetist and CPEX Lead at the Maidstone Hospital, the local hospital to the 
Control group of patients. The Intervention group underwent CPEX testing by a Specialist Exercise 
Physiologist at CHHP, who also provided the additional exercise training of the prehabilitation 
Intervention participants. 
CPEX testing in the Interventional group was performed on an ergoline 900 model cycle 
ergometer. It is electromagnetically braked, and resistance is modulated automatically to a set 
work rate based on cadence. The protocol that was selected was a ramp protocol. The ramp 
speed in Watts.min-1 was selected based on predicted VO2 and adjusted to the individual. 
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An Ergoline Ergoselect 200 cycle ergometer was used in the Control group according to the same 
protocol as the Intervention group. 
Peak Oxygen Uptake (VO2peak, ml.kg-1.min-1) and anaerobic threshold (AT, ml.kg-1.min-1) were 
recorded as the appropriate measures for fitness and fitness changes in this group of patients. 
 
7.4 Results 
Table 7-1 Anaerobic Threshold (ml.kg-1.min-1) 
 Control group Intervention group 
 
 N=14 N=13 
 
 Median (IQR) 
% 
Change 
vs 
Baseline 
Median (IQR) 
% Change  
vs 
Baseline 
 
 
 
p-value 
Baseline  14.2  (13.1-17.6)  17.9 (16.9-20.3)  0.08 
Post-NAC  11.5  (10.2-13.3) -19% 14.4  (13.0-16.8) -20% 0.02 
Pre-Surgery  13.3  (11.5-15.2) -6% 14.5  (13.4-17.2) -19% 0.06 
Post-surgery  12.1 (10.2-13.9) -15% 13.9  (11.9-15.5) -22% 0.17 
 
There was a marked deterioration of AT in both Control and Intervention groups, of up to 20%, 
with better recovery towards baseline in the Control cohort and further decline in both groups 
after surgery.  
 
Table 7-2 VO2peak (ml.kg-1.min-1) 
 Control group Intervention group 
 
 
p-value 
 N=14 N=13 
 Median (IQR) 
% Change 
vs 
Baseline 
Median (IQR) 
% Change  
vs 
Baseline 
Baseline  22.5 (19.6-26.3)  27.9 (26.5-31.1)  0.03 
Post-NAC  18.3 (17.9-21.2) -19% 24.5 (20.4-27.4) -12% 0.01 
Pre-Surgery 20.1 (19.1-24.6) -11% 25.5 (22.5-29.5) -9% 0.01 
Post-surgery 18.1 (15.9-21.0) -20% 20.6 (16.7-25.1) -26% 0.24 
 
 
 
Structured exercise prehabilitation resulted in better outcomes in oxygen consumption in the 
Interventional group with median VO2peak demonstrating a blunted fitness deterioration of 7% 
70 
 
 
with an overall decline of 12%, compared to the Control Cohort’s deterioration of 19% (see 
Figure 7-1).  
 
 
Figure 7-1 Graph representing VO2peak changes 
  
Figure 7-2 Ladder plot of individual VO2peak changes: Intervention and Control groups. Baseline, 
Post-NAC, and Pre-surgery 
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(For earlier interim results also see Appendix B and Appendix C - Scientific Abstract & Poster: 
DOI: 10.1249/01.mss.0000561780.97589. June 2019 Medicine & Science in Sports & 
Exercise 51(Supplement):427 “Feasibility of exercise prehabilitation during neo-adjuvant 
chemotherapy in oesophago-gastric cancer surgery”.) 
7.5 Discussion 
Figure 7-2 graphically represents individual VO2peak changes within each of the Intervention and 
Control groups. It is noted that the VO2peak results were overall lower in the Control group. The 
underlying reason for the discrepancy between the groupings is likely to be as a result of the 
higher median BMI in participants the Control versus Intervention groups (28.3 kg.m-2 vs. 24.7 
kg.m-2). 
 
Reduced AT in both groups indicates reduced cardiorespiratory reserve through neo-adjuvant 
chemotherapy deconditioning. Navidi et al. suggested that a decline in AT was predictive of post-
operative morbidity (Navidi et al., 2018). According to NOGCA post-op complications 
classification, 4 cases of pneumonia were reported in the Intervention group which is in line with 
this prediction. Higher smoking status in the Intervention group may also underly the reduced 
cardiorespiratory reserve and subsequent respiratory complications in these patients despite the 
exercise prehabilitation. Patients who smoke are known to be at higher risk of pulmonary disease 
and post-op complications. The period of exercise prehabilitation, and with added cardiovascular 
toxicity from chemotherapy, may not be long enough on the current standard pathway to 
compensate for the negative effects of smoking. Smoking cessation should become compulsory 
to reduce pulmonary complications in patients that undergo this type of surgery. 
(See Chapter 6 for surgical outcomes.) 
 
This level of fitness deterioration observed in this study  is concordant with other published data 
in similar cohorts of patients (Sinclair et al., 2016). It is unlikely that any exercise program will 
negate or reverse the physical deterioration of patients undergoing chemotherapy. The 
reduction or blunting of deterioration, in participants in the Intervention group, as measured by 
VO2peak, is an encouraging result in an intervention period of only 8 to 9 weeks during concurrent 
chemotherapy.  
Patients in both Control and Intervention groups improved in fitness in the post-NAC period 
before surgery. However, with a further 5 to 6 weeks of prehabilitation prior to surgery, overall 
72 
 
 
fitness deterioration in the Intervention group continued to show less overall deterioration 
compared to the Control group (-9% vs. -11%).  
 
7.6 Conclusions 
A structured exercise prehabilitation program during neo-adjuvant chemotherapy reduces 
chemotherapy-associated deconditioning in VO2peak compared to patients undergoing a standard 
treatment pathway. The reduced deterioration in oxygen uptake is provided by a supported, 
structured exercise prehabilitation program which should ideally be made available to all cancer 
patients who are willing to undertake such an exercise intervention. 
Further collaborative research is indicated in larger patient cohorts and in patients on non-
surgical and ‘non-curative’ cancer treatment pathways. 
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Chapter 8  Body Mass and Body Composition 
 
8.1 Background 
There is linear association between higher Body Mass Index (BMI) and incidence of upper 
gastrointestinal (oesophagus and stomach) cancers, independent of smoking status (Bhaskaran 
et al., 2014; Coe, O’Reilly and Renehan, 2014). More specifically, the prevalence of oesophageal 
adenocarcinoma is associated with an increased BMI in men (Renehan et al., 2008). 
Obese patients are also at risk of increased rates of tumour growth and disease progression (Park 
et al., 2014). Furthermore, there is evidence linking an increased visceral obesity with poorer 
clinical outcomes and changes in body composition in patients undergoing neo-adjuvant 
chemotherapy in oesophageal cancer (Yip et al., 2014b, 2015), and a strong carcinogenic 
association of  visceral adipose tissue enhancing tumorigenesis in epithelial tissue (Renehan, 
Zwahlen and Egger, 2015; Chakraborty et al., 2017). Depletion of skeletal muscle mass is a poor 
prognostic factor in cancer  (Martin et al., 2013) while inactivity and ageing are known to be 
associated with loss of skeletal mass and function, with a loss of 1% to 5% per year in middle age 
(Wilkinson, Piasecki and Atherton, 2018).   
In the recent Continuous Update Project (CUP) presented by the World Cancer Research Fund 
collaboration in 2018, ‘convincing evidence of body fatness’ was stated to increase the risk of all 
cancers including oesophageal adenocarcinoma, while ‘physical activity and vegetables’ was 
reported to ‘suggest’ a decreased risk (“Diet, Nutrition, Physical Activity and Cancer: a Global 
Perspective”. About the Third Expert Report, no date; Oesophageal cancer | World Cancer 
Research Fund International, no date). 
 
8.2 Aim 
This study aimed to assess the impact of a structured exercise program versus standard care on 
body mass and body composition using the routine Computerised Tomography (CT) scans of 
patients before and after neo-adjuvant chemotherapy. 
 
8.3 Methods 
The use of CT scans for quantifying fat or adipose tissue (FAT), visceral fat and muscle tissue at 
the 3rd lumbar vertebral level (L3) has opened the opportunity for assessment of adiposity and 
sarcopenia in research and clinical settings (Mourtzakis et al., 2008). The same group also linked 
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body composition, using CT scans, to sarcopenic obesity and clinical outcomes in oesophageal 
cancer treatment (Prado et al., 2008) 
In this study, patients in both Intervention and Control cohorts underwent routine pre- and post- 
neoadjuvant chemotherapy CT scans for disease staging purposes.  The images were assessed, 
using FATS software developed at King’s College London, within a standard Digital Imaging and 
Communications in Medicine (DICOM) process for tissue segmentation. Assessments were 
supervised by Professor Vicky Goh, Professor of Cancer Clinical Imaging, and performed by 
Radiology Clinical Research Fellow, Dr Louise Gervais-Andre. 
 
Using Hounsfield unit thresholding, automated segmentation of subcutaneous and visceral fat 
and muscle parameters was evaluated in each participant. The equivalent of 10mm slices (z-axis 
image stacks) were sampled at L3 from the CT scans. Layers of the abdominal wall (skin, 
subcutaneous fat and skeletal muscle), intra-abdominal layers (visceral layers and viscera) and 
vertebral bone including spinal cord were delineated manually by a qualified radiologist. 
Automated segmentation of subcutaneous and visceral fat, and muscle parameters enabled 
tissue attenuation correlating with standardised values identifying skeletal muscle, visceral 
muscle, and fat (Mourtzakis et al., 2008). (See Figure 8.1) 
 
Segmented values of skeletal muscle, visceral and subcutaneous fat were obtained.  
Using height and weight data at the relevant time points, the following standardised calculations 
were made (Mourtzakis et al., 2008): 
Total body FM (kg) = 0.042 × [total adipose tissue at L3 (cm2)] + 11.2 
Total body FFM (kg) = 0.3 × [skeletal muscle at L3 (cm2)] + 6.06 
FM and FFM were normalised for stature to derive FM index (FMi) and FFM index (FFMi)(kg.m-2) 
respectively: 
FM index (kg/m2) =Total body FM ÷ [height × height (m2)] 
FFM index (kg/m2) =Total body FFM ÷ [height × height (m2)] 
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Figure 8-1 CT body composition segmentation at Lumbar 3 vertebrae: a) Subcutaneous 
boundary, b) Skeletal muscle boundary, c) Vertebral boundary, d) Visceral boundary, e) Fat 
segmentation 1, f) Fat segmentation 2 
 
8.4 Results 
An overall increase in FFMi and loss of FMi was observed in patients participating in the exercise 
prehabilitation program, with the opposite overall change in the Control group with this group 
also presenting with a weight increase. The increased weight in the Control group was mainly in 
the visceral fat, an increase of 4.5%, with a 2.5% increase in subcutaneous fat. The Interventional 
group had a greater median decrease of visceral fat compared to subcutaneous fat of 7.4% and 
 
76 
 
 
5.10%, with a median weight loss of 0.6% compared to baseline (see Table 8.1 and 8.2). 
Table 8-1 Body composition parameters: Intervention versus Control groups 
      Control  Intervention  
p- values* 
 n=14 n=13 
Parameters Mean (SD) Range Mean (SD) Range 
 Median (IQR)  Median (IQR)   
FFM index (kg/m2)      
Baseline 15.4 (3.6) 10.3-22.4 17.4 (4.4) 9.2-24.1 0.23 
 16.3 (11.8-18.5)  17.8 (14.4-20.9)   
Post NAC 15.4 (3.0) 9.4-18.8 17.7 (3.7) 12.5-23.3 0.03 
 14.7 (12.3-17.3)  18.7 (15.0-20.2)   
Changes (%) -3.0 (22.1) -45.0-42.5 4.3 (16.9) -18.5-41.3 0.36 
 -1.9 (-19.0-9.9)  2.3 (-7.2-10.1)   
FM index (kg/m2)      
Baseline 8.5 (2.2) 4.1-11.8 8.9 (3.6) 4.9, 16.2 0.96 
 8.1 (7.1-10.4)  9.1 (6.4-9.6)   
Post NAC 8.7 (1.9) 5.5-12.2 8.8 (3.1) 4.8, 15.0 0.70 
 8.2 (7.4-10.5)  8.2 (6.8-9.2)   
Changes (%) 3.5 (10.7) -6.9-34.7 0.7 (14.7) -12.4-35.1 0.21 
 0.7 (-3.7-5.8)  -3.8 (-9.8-3.8)   
FMR      
Baseline 1.31 (0.78) 0.14-3.12 1.31 (0.96) 0.17-3.34 0.85 
 1.07 (0.90-1.58)  1.08 (0.67-1.75)   
Post NAC 1.45 (0.63) 0.41-2.78 1.25 (0.76) 0.15-2.47 0.41 
 1.11 (0.88-2.16)  0.91 (0.59-1.94)   
Changes (%) 26.3 (61.3) -31.6-200.0 8.4 (41.9) -38.9-104.9 0.50 
 12.4 (-11.9-36.6)  -7.15 (-17.2-39.2)   
Visceral fat (cm2)      
Baseline 202.9 (104.9) 25.5-376.0 186.0 (128.0) 27.0-468.3 0.70 
 206 (141-274)  204 (41-256)   
Post NAC 211.0 (86.8) 42.4-351.2 173.2 (114.4) 25.0-433.7 0.21 
 214 (163-249)  154 (104-228)   
Changes (%) 25.3 (66.5) -15.1-247.0 10.9 (54.9) -36.2-150.3 0.13 
 4.5 (-5.1-28.7)  -7.4 (-23.2-12.7)   
Subcutaneous  
fat (cm2)     
Baseline 173 (91) 25-367 179 (126) 33-463 0.81 
 165 (112-183)  153 (109-214)   
Post NAC 176 (79) 72-330 179 (106) 30-420 0.77 
 158 (129-190)  147 (111-227)   
Changes (%) 15.2 (52.0) -18.3-191.9 10.3 (37.9) -30.8-101.5 0.47 
 2.5 (-5.1-9.2)  -5.1 (-9.4-9.3)   
VA/SA ratio      
Baseline 1.30 (0.74) 0.16-3.29 1.08 (0.62) 0.24-2.47 0.31 
 1.24 (0.84-1.50)  0.83 (0.61-1.51)   
Post NAC 1.31 (0.63) 0.30-2.84 1.04 (0.55) 0.25-1.97 0.36 
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 1.22 (0.99-1.41)  0.83 (0.59-1.39)   
Changes (%) 8.9 (26.2) -18.0-87.0 -1.31 (20.6) -31.7-36.6 0.47 
 2.0 (-4.7-15.2)  1.70 (-17.2-10.1)   
Weight (kg)      
Baseline 91.1 (27.1) 61.7-170 76.0 (13.5) 56.8-99.6 0.05 
 87.5 (68.7-94.5)  80.1 (64.3-84.3)   
Post NAC 92.1 (26.5) 63.8-169 75.6 (12.7) 56.0-96.9 0.05 
 88.2 (74.0-95.6)  76.4 (69.2-79.9)   
Changes (%) 1.5 (3.7) -6.7-8.4 -0.13 (4.9) -8.6-8.1 0.36 
 1.2 (-0.6-3.5)   -0.6 (-2.7-4.6)   
 FFM-fat free mass, FM – fat mass, FMR – subcutaneous fat to muscle ration, VA/SA ratio – visceral to subcutaneous 
fat (adipose tissue) ratio, BMI- body mass index 
*p-values derived from Wilcoxon-signed rank test 
 
Table 8-2 Summary of body composition changes after NAC 
Parameters Intervention  Controls  
FFM index (kg.m-2) 2.30% -1.90% 
 FM index (kg.m-2) -3.80% 0.70% 
 FMR -7.15% 12.40% 
 Weight (kg) -0.50% 1.20% 
 Visceral fat (cm2) -7.40% 4.50% 
 Subcutaneous fat (cm2) -5.10% 2.50% 
 
 
 
Figure 8-2 Bar chart showing body composition and weight changes post-NAC 
-10% -5% 0% 5% 10% 15%
FFM index (kg/m2)
FM index (kg/m2)
FMR
Weight
Median change
FFM index
(kg/m2)
FM index
(kg/m2)
FMR Weight
Intervention 2.30% -3.80% -7.15% -0.60%
Control -1.90% 0.70% 12.40% 1.20%
Fat, Muscle and Weight changes after NAC
Intervention Control
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8.5 Discussion 
The observed increases in FFM and height adjusted FFMi combined with the decrease in FM 
and FMi in patients participating in the exercise intervention during NAC compared with the 
opposite increases in FM and FMi with synchronous decrease in FFM and FFMi, is another 
unexpected result from this trial.  
Patients diagnosed with oesophageal cancer frequently present with nutritional deficiencies and 
weight loss due to disease-associated difficulties with swallowing. Oesophageal tumours may 
cause obstruction, regurgitation or pain during eating with subsequent diet restriction. Despite 
this, patients in the Intervention group remained weight stable with an increase in muscle 
development and reduction in fat. In contrast, patients in the Control group gained weight. The 
weight-gain occurred mainly as fat but particularly as visceral fat – known to be associated with 
tumour and disease progression.  
The improvement in body composition in oesophageal cancer patients undergoing a structured 
exercise program during simultaneous chemotherapy treatment is a positive and clinically 
relevant outcome from this trial. 
 
8.6 Conclusions 
There were significant and striking differences between the Intervention and Control groups in 
relation to body composition changes in patients undergoing 8-9 weeks of neo-adjuvant 
chemotherapy. It was hypothesised that a reduction of sarcopenia would be achieved over this 
relatively short period of exercise intervention – and under difficult circumstances for the 
patients - whereas an overall reversal of sarcopenic obesity  occurred in patients on the 
Interventional prehabilitation program. The opposite effect was noted in the Control cohort on 
a standard care pathway.  
This contrast in body composition changes between the groups following neo-adjuvant 
chemotherapy and the potential deleterious role of increased fat on the tumour micro-
environment is cause for clinical re-evaluation of the information on exercise and diet that is 
currently provided to patients. 
Further collaborative research, in larger cohorts of patients is indicated to validate the results in 
this study. 
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Chapter 9  Immunity and Inflammatory Blood Markers 
 
9.1 Background 
The effect of exercise prehabilitation in cancer may impact tumour control through immune 
system regulation. In a review of patients who undertook monitored exercise following a 
diagnosis of cancer, there was a lower relative risk of cancer recurrence and cancer-related 
mortality compared to patients who did little or no exercise. Furthermore, the same patients 
experienced fewer or less severe treatment side effects (Cormie et al., 2017). This finding 
supports the suggested immunological component to cancer growth and recurrence control. 
Terra et al. (2012) described inherent activation of the immune response cascade through 
exercise, eliciting a pro-inflammatory response during moderate intensity exercise. However, 
during high intensity exercise an anti-inflammatory response was noted. Hojman further 
described the effects of exercise on the control of immune cell function, modulation of 
inflammatory signalling and regulation of systemic inflammation linking these regulatory effects 
to lowered tumour incidence and disease progression (Hojman, 2017a). Pederson et al. (2016c) 
linked exercise to reduced tumour growth through increased infiltration of natural killer (NK) cells 
in exercised mice. The mechanism of increased mobilization of NK cells is speculated to be 
through increased release of Interleukin-6 (IL-6) myokines in response to muscle contraction 
(Idorn and thor Straten, 2017). Exercise-induced IL-6 is described as having a pro-inflammatory 
effect on bacterial infections and a contrasting anti-inflammatory inhibiting effect on Tumour 
Necrosis Factor-alpha (TNF-a) (Cullen et al., 2016) .  
The tumour micro-environment (TME) is therefore one in which a balance of tumour-promoting 
and tumour-suppressing signals is under constant surveillance and regulation by the immune 
system. In cancer, these signals are interrupted and imbalanced in favour of cell-growth. Exercise 
has been observed to have a tumour regulation effect (Pedersen et al., 2016c). This effect is 
multifactorial. When the TME is under stress it is thought to release growth factors, with oxygen 
depletion a major stressor implicated in tumour regulation (Petrova et al., 2018). 
In addition, pro-inflammatory and inflammation-suppressing cytokines are released during 
exercise thereby assisting the immune system in regulation of the TME. Study of the TME is 
complex and pathological tissue samples are not always available. It has been shown, however, 
that the peripheral blood T-cell activity closely correlates with the activity within the TME 
providing a useful method of monitoring immune and inflammatory function during treatment 
(Iwahori et al., 2019). 
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9.2 Aim 
The aim of this study was to investigate the effect of exercise on immunity and inflammatory 
markers in patients on a combined chemotherapy-surgical pathway for oesophageal cancer using 
peripheral blood samples taken at the key study time points. This information would provide 
some insight into the TME in cancer patients undertaking exercise prehabilitation. 
 
9.3 Methods 
Blood samples were taken according to the study protocol. 
Blood samples for Immunoglobulins (IG) and Lymphocyte subsets (LS) were analysed 
immediately while samples for Cytokine analysis were spun, stored and frozen for later batch 
testing and analysis. 
9.3.1 Immunoglobulins 
Immunoglobulins are measured using serum and plasma samples of patient’s blood. A 
mechanised assay is used following addition of polyethylene glycol (PEG) to stimulate antigen-
antibody reaction. Agglutination occurs resulting in increased turbidity. Turbidity is then 
measured, in nanometres (nm). A calibration curve is constructed and the absorbances 
determined calculate IgG, IgA and IgM concentrations.  
9.3.2 Lymphocyte subsets  
T-Lymphocyte subsets are analysed using Laser Flow Cytometry of a monoclonal antibody/blood 
sample reaction on a Beckman Coulter AQUIOS flow cytometer ( BECKMAN COULTER Life 
Sciences, 5350 Lakeview Parkway S Drive, Indianapolis, IN 46268, USA) . Red cells are lysed 
through addition of a lysing solution. A stream of the remaining single cells of antibody-antigen 
reaction, are passed through a laser beam interrogation point. The emitted light passes through 
wavelength filters separating out the subset components. The results are produced as a series of 
histogram plots and analysed according to grouping. Manual ‘gating’ is carried out by an 
Immunologist for quality control. 
9.3.3 Cytokines 
Groups of cytokines - lymphokines, interferons, haemopoietic and non-haemopoietic growth 
factors were measured through quantitative detection of multiple analytes on a RANDOX 
Evidence Investigator (Randox Laboratories Ltd. 140 London Wall, London, EC2Y 5DN) using 
Competitive and Sandwich antibody, chemiluminescent, biochip immunoassays. Increased 
binding of horseradish-labelled antibody with the analytes, resulted from increased cytokine 
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levels in a specimen. A chemiluminescent response between the cytokine antigen and the HRP-
labelled antibody was detected using digital imaging technology. 
 
9.4 Results 
The mean percentage changes, with standard deviation (SD), at each time point were analysed 
comparing baseline immunity and inflammatory blood results within Control and Interventional 
cohorts. 
(see Appendix DE for full results: Table 9.2 - Immune markers, and Table 9.3 – Inflammatory 
markers; Figure 9-2 CD3+/CD4+ Histogram plot examples) 
 
The post-NAC results summarised in Table 9.1, indicating those parameters which had greater 
than 25% difference in change between the Control and Intervention cohorts from Baseline to 
Post-NAC  
 
Table 9-1 Percentage change in Immunity and Inflammatory Markers: Baseline to Post-NAC 
  Control  Intervention     
Markers % Mean change % Mean change % Mean Difference  p-values 
Immunity      
CD3 (cells/uL) 4.53 34.26 29.73 0.03 
CD4 (cells/uL) 9.36 42.08 32.72 0.1 
CD8 (cells/uL) 0.98 29.41 28.43 0.03 
Inflammatory      
IL-6 (ng/L) 126.41 27.93 -98.48 0.04 
VEGF (ng/L) 51.79 10.51 -41.28 0.27 
INF-y (ng/L) 223.64 57.24 -166.4 0.36 
TNFa (ng/L) 28.31 -1.77 -30.08 0.24 
MCP-1 (ng/L) 169.69 52.11 -111.58 0.09 
EGF (ng/L) -8.23 20.06 28.29 0.61 
     
 
There was a significantly different increase of % Mean change in T-Lymphocytes CD-3 and CD-8 
in the Intervention group when compared to the Control group after NAC (34.26% and 29.08% 
vs. 4.53% and 0.98%, p=0.03 for both CD-3 and CD-8). 
IL-6 resulted in a moderate increase in the Intervention group after NAC compared to a 
significantly greater increase of this inflammatory marker in the Control group (126.41% vs. 
27.93%, p = 0.04).  
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TNFa was reduced by -1.77% in the Intervention group but increased by 28.31% in the Control 
group after NAC. 
INF-y showed a 223.64% increase in the Control group compared to the moderate change of 
57.24% in the Intervention group. 
MCP-1 change was lower in the Intervention group  while being markedly increased in the Control 
group (52.11% vs. 169.69%). 
 
 
 
Figure 9-1 Percentage change in Immunity and Inflammatory markers after NAC 
 
9.5 Discussion 
The increase, and statistically significant (p ≤ 0.05) difference, in T lymphocytes CD-3 (p = 0.03) 
and CD-8 (p = 0.03), in patients who exercised during neo-adjuvant chemotherapy suggests 
improved adaptive immune-system function and tumour-cell destruction capability, compared 
to patients in the Control cohort. Recent reports suggest that CD-3 and CD-8 as being predictive 
of improved response to NAC in breast cancer patients while other suggest their value in being 
prognostic of decreased cancer relapse (Brown et al., 2014; Tsiatas et al., 2018). This hypothesis 
appears to correlate with the reported improved Mandard Tumour Regression Grade scores 
discussed in Chapter 6. 
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IL-6 induced through exercise (muscle stimulation) has been reported to having a role in immune 
regulation (Hojman et al., 2018)  while IL-6 secretion related to visceral adiposity is reported to 
be directly associated with tumour cell growth and disease progression (Park et al., 2014). 
Furthermore, IL-6 and TNFa  are reported to strongly correlate with increased BMI (Park, Park 
and Yu, 2005). These hypotheses correlate with the moderate increases in IL-6 in the Intervention 
group – suggestive of resulting from muscle activation, while the greater change in IL-6 in the 
Control group, with synchronous increase in TNFa, suggesting activation through increased 
visceral fat stimulation in the Control group. This appears to be linked to the increase in visceral 
fat increase noted on CT scan in participants in the Control group. (Chapter 8) 
Previously considered to have antitumor immunity properties, IFN-y has recently been found to 
have a converse, tumour-progressive function. The mechanism of this tumour progressive role is 
thought to be through immune-system evasion of cancer cells and is a topic of current 
exploration (Mojic, Takeda and Hayakawa, 2017; Zaidi, 2019). INF-y changes in the Control group 
were highly elevated compared to the Intervention group suggesting greater levels of immune-
system evasion resulting in decreased tumour control.    
MCP-1, believed to regulate the tumour cell and macrophage cycle promoting progression of 
tumours (Yoshimura, 2018) showed much greater changes in the Control group compared to the 
Intervention group. In vivo studies of mice with ovarian cancer, MCP-1 appeared to increase cell 
migration and invasion of tumour cells (Rattan et al., 2019). In our study, 2 patients in the Control 
group were reported to have cancer recurrence within the follow-up period, with none in the 
Intervention cohort. Exercise would appear to moderate expression of MCP-1 and therefore have 
a controlling effect on tumour cell migration and disease relapse. 
 
9.6 Conclusions 
Statistically significant and correlating results in T Lymphocyte activation of CD-3, CD-8, and IL-6 
were observed indicating that the exercise Intervention group appeared to experience improved 
cancer control at a molecular level. These results are particularly encouraging in  patients who 
had recently finished immune-suppressive chemotherapy. In contrast, T- Lymphocyte results in 
the Control cohort showed suppressed immunity and high levels of inflammatory cytokines (IL-
6, TNFa, INF-y and MCP-1) indicating unregulated or progressive inflammation in the TME.  
Accordingly, data from the present study demonstrates a positive impact of structured exercise 
supporting the immune system despite chemotherapy suppression during NAC while moderating 
inflammatory responses. 
84 
 
 
Chapter 10  Health-Related Quality of Life 
 
10.1 Background 
An area of increased focus in patients with cancer is the impact of the diagnosis, treatment and 
survival, on their quality of life. The United Nations defines quality of life as the “notion of human 
welfare (well-being) measured by social indicators rather than by ‘quantitative measures of 
income and production” (UNdata | glossary). In the context of cancer and health, quality of life 
extends beyond the ‘impact of treatment and side-effects, but to the recognition of the patient 
as an individual, and as a whole person, body mind and spirit’ (Calman, 1984). In practice, quality 
of life measures are those self-reported measures of changes in a person’s circumstances 
reflecting the fulfilment of hopes and expectations, or lack thereof.  
Validated Health-related quality of life (HRQL) questionnaires assess multiple facets of quality of 
life including: wellbeing; and physical, emotional, cognitive and social functioning; in addition to 
specific symptom scores. Studies have shown that HRQL is negatively impacted by oncological 
treatments (Noordman et al., 2018) with a slow recovery after surgery (Djärv et al., 2008; 
Safieddine et al., 2009; Kidane et al., 2018). Djarv et al.,(2008), (Noordman et al., 2018 and Kidane 
et al., 2018), reported that HRQL only returned to baseline 6 to 36 months after oesophagectomy. 
In oesophageal cancer, neo-adjuvant chemotherapy or chemoradiotherapy has been reported to 
result in an overall decline in HRQL (Blazeby et al., 2005). Poor health and mental wellbeing are 
common hallmarks following a diagnosis of cancer and after undergoing cancer treatment, in the 
UK (Elliott et al., 2011).  
Of note, increased physical activity and exercise is associated with improved Health-related 
Quality of Life in the general population (Anokye et al., 2012) and improved mental wellbeing, 
especially in later life (Windle et al., 2010).  Post-surgical studies in breast cancer patients have 
shown that engaging in physical activity helps to manage the decline in HRQL after surgery (Leach 
et al., 2015).  
 
10.2 Aim 
This study aimed to examine self-reported Mental Wellbeing and HRQL in patients undertaking 
an exercise prehabilitation program during NAC versus patients on a standard care pathway. 
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10.3 Methods 
The trial employed two validated questionnaires: A cancer-specific questionnaire, EORTC QLQ-
C30 and the shortened Warwick-Edinburgh Mental Well-being scale (SWEMWBS) to evaluate 
patient reported outcomes (PROMS).  
The EORTC PROMS were developed and validated for cancer-specific measures and useful 
irrespective of the level of advancement of cancer (EORTC | European Organisation for Research 
and Treatment of Cancer : EORTC). 
A collaboration between Warwick and Edinburgh Universities produced the Warwick-Edinburgh 
Mental Well-being scale (WEMWBS) for assessing mental wellbeing in the general population. In 
this study, the shortened version, SWEMWBS, was employed to reduce the burden of 
‘questionnaire-fatigue’ on the patient. 
Patients were asked to complete self-reported questionnaires at all major time points of the trial 
and at 6 and 12 months after surgery. EORTC QLQ-C30 (Quality of Life of Cancer Patients) and 
the SWEMWBS questionnaires were selected following registration with the relevant 
organisations. Published specified module guidelines were used for analysis. 
Voluntary feedback comments from patients are also included in Appendix F. 
 
10.4 Results 
Mean scores with standard deviations were calculated from the completed questionnaires for 
patients at baseline and all subsequent time points. Questionnaires were composed of many 
questions, largely designed for research purposes of large cohorts, but also for use in clinical 
assessment. The numbers of patients in this analysis are insufficient to achieve any statistically 
significant results but were expected to produce a trend of any difference in effect between 
patients in the two patient groups. 
Some groupings of mixed results were achieved; however, some groupings produced a more 
consistent trend. These can be seen graphically represented in Figures 10-1, 10-2 and 10-3 
(Appendix E: Table 10-1) 
 
10.4.1 Mental Wellbeing 
Figure 10-1 demonstrates an overall benefit of exercise participation in the Intervention group 
with an improved WEMWBS and a reduced perturbation in mental wellbeing, with near return 
to baseline at 12 months after surgery. In comparison, participants in the Control group showed 
a large decline in Mental Wellbeing after NAC and at 6- and 12-months after surgery. 
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Figure 10-1 Mental Wellbeing scores (WEMWBS) 
 
10.4.2 Health Related Quality of Life 
Figures 10-2 and 10-3 represent the EORTC QLQ C30 self-reported questionnaires evaluating 
HRQL using function- and symptom- related questions. In similarity to the SWEMWBS results, 
Emotional Functioning was markedly better in the Interventional group who undertook the 
exercise program. Similar results in both groups were noted in Social- and Role- Functioning 
except for an unexplained sharp decline in Role Function at 6 and 12 months in the Intervention 
group. Questions on Physical- and Cognitive-Function scores produced mixed results in both 
groups however a near return to baseline function was achieved at 12-months post-surgery. 
 
 
 
 
-8.0%
-6.0%
-4.0%
-2.0%
0.0%
2.0%
4.0%
6.0%
Baseline to Post-
NAC
Baseline to Pre-
surgery
Baseline to
adjuvant chemo
Baseline to 6
months post-op
Baseline to 12
months post-op
P
er
ce
n
ta
ge
 c
h
an
ge
Timepoints
Mental Wellbeing
Control Intervention
87 
 
 
a) 
b) 
c) 
 
-10.0%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
Baseline to
Post-NAC
Baseline to
Pre-surgery
Baseline to
adjuvant
chemo
Baseline to 6
months post-
op
Baseline to 12
months post-
op
P
er
ce
n
ta
ge
 c
h
an
ge
Timepoints
Physical Functioning
Control Intervention
-20.0%
-10.0%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
Baseline to
Post-NAC
Baseline to Pre-
surgery
Baseline to
adjuvant
chemo
Baseline to 6
months post-
op
Baseline to 12
months post-
op
P
er
ce
n
ta
ge
 c
h
an
ge
Timepoints
Role Functioning
Control Intervention
-20.0%
-15.0%
-10.0%
-5.0%
0.0%
5.0%
10.0%
15.0%
20.0%
Baseline to
Post-NAC
Baseline to Pre-
surgery
Baseline to
adjuvant
chemo
Baseline to 6
months post-
op
Baseline to 12
months post-
op
P
er
ce
n
ta
ge
 c
h
an
ge
Timepoints
Emotional refunctioning
Control Intervention
88 
 
 
d) 
e) 
Figure 10-2 EORTC QLQ C30 Grouped Functioning Scores –a,b,c,d,e 
 
Results varied among the cancer-specific symptoms. There appeared to be greater fluctuations 
in insomnia in the Control group.  Appetite variation was also greater in the Control group. Overall 
weight gain was noted in this group compared to the Intervention group while undertaking the 
structured exercise program. Constipation also fluctuated more in the Control versus 
Intervention group. 
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a) 
b) 
c) 
Figure 10-3  EORTC QLQ C30 Selected Symptom Scores – a,b,c
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10.5 Discussion 
A cancer diagnosis has a powerful effect on an individual. Despite reduced self-reported outcome 
scores in the Intervention group they still produced good scores on Mental Wellbeing and 
Emotional Function compared to their study counterparts. 
The confounding variables which may have impacted on the results in cancer-specific symptoms 
are numerous and more likely related to the disease status rather than to exercise-related 
physical activity, especially pain, nausea, and diarrhoea.  
Constipation was markedly reduced in the exercise Intervention group but increased by more 
than 10% compared to baseline in the Control group. In a study of regular exercise on chronic 
constipation in middle-age adults, regular physical activity reportedly improved symptoms (De 
Schryver et al., 2005).  Appetite loss was lower in the Control group compared to an increased 
appetite loss in the Intervention group. This corresponds with the increase in overall weight and 
body fat in the Control group during neo-adjuvant chemotherapy (discussed in Chapter 8.4) but, 
does not seem to have had a negative Mental Wellbeing effect in the Intervention group who 
increased muscle mass without weight loss, despite reduced appetite. 
From anecdotal evidence, it was noted that many of those who undertook the exercise 
intervention self-referred to physiotherapy and rehabilitation support services in the post-12-
month follow-up period. This was encouraging as few had regularly participated in exercise or 
physical activity prior to their diagnosis of cancer. In contrast, the Control cohort, while scoring 
slightly better pre-surgery, scored lower after neo-adjuvant chemotherapy and were still 
struggling to return to baseline Mental Wellbeing at 12 months after surgery. 
On completion of the trial at 12-months post-op, patients were invited to provide feedback and 
comments relating to their participation in the exercise prehabilitation. (See letters in Appendix 
E) 
 
10.6 Conclusions 
There was an overall improvement in Mental Wellbeing, and corresponding improvement in 
Emotional Refunctioning in HRQL after neo-adjuvant chemotherapy and at 6- and 12-months 
post-surgery in patients that participated in a structured exercise prehabilitation program. The 
chemotherapy and surgery treatment periods are arguably significantly ‘negative’ periods during 
the patient pathway. To achieve the difference in Mental Wellbeing at major time points in the 
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Interventional group supports the role of exercise intervention peri-treatment in oesophageal 
cancer patients.  
Participation in the exercise program appeared to provide short-term benefits in the neo-
adjuvant treatment period and longer-term benefits with many patients being self-motivated to 
enrol in physical activity and exercise programs in the post-treatment and ‘Survivorship’ period.  
Clinical outcomes and disease-free survival analysis using correlation of HRQL in this study are 
recommended once both groups of patients have completed all aspects of the treatment 
pathway including 12 months of follow-up. 
Results of the HRQL scores showed mixed and variable differences between the two study 
groups. The small numbers of patients and large number of variables being assessed were 
perhaps inappropriate for this interim analysis. The relevance of the questions in the self-
reported outcome questionnaires may be more valuable in studies investigate the specific areas 
under scrutiny in the questionnaires. 
 
Qualitative feedback from patients highlighted areas not specifically covered in the 
questionnaires but relevant to the patient outcomes, for example: 
• Something to focus on other than the diagnosis and treatment 
• A reason to ‘get out of the house’ 
• ‘Going motivated me to get out and about’ 
• ‘I felt much better after each session’ 
• ‘the simple fact of going gave me a purpose and the exercise boosted my morale which 
had been sapped by the chemo’ 
• ‘The staff….watched me and made sure that I was comfortable and safe at all times’ 
These are important ‘take home’ messages for those directing treatment pathways in cancer 
care. 
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Part C 
Chapter 11  General Discussion 
 
The aim of the Pre-EMPT clinical trial was to assess the feasibility of a structured exercise 
prehabilitation program for patients on an operable, ‘curatively-intended’ peri-operative 
treatment pathway. 
Inherent in some of the challenges to recruiting patients into the study, were the lifestyle factors 
associated with the increased risks of developing oesophageal adenocarcinoma, including: GORD 
(gastro-oesophageal reflux disease); obesity; low levels of physical activity and sedentary 
lifestyles; and smoking. These factors were also some of the challenges faced in retaining 
participants in the Intervention group of the study. In this group, there was a higher non-
participant/self-withdrawal rate in the study than in the Control group who received standard 
care. Barriers to participation in physical activity and exercise programs is a burgeoning topic of 
interest, debate and research (Justine et al., 2013). When considering the implementing of 
structured activity/exercise programs for patients as standard care, aspects of the availability and 
location of facilities, patient motivation, cost, instruction and activity monitoring are just some 
of the factors which require further investigation and refinement. In the present thesis, some of 
these aspects are mentioned in the patient feedback letters (Appendix F). 
 
In this study, 13 of the original 20 patients that initially consented to participate in the exercise 
Intervention group completed the requirements of the trial (see Chapter 5). While, inevitable, 
during the period of the program there were days, if not weeks when patients did not feel 
physically capable or psychologically motivated enough to be active, the overall results indicate 
that a structured exercise prehabilitation program during neo-adjuvant chemotherapy and 
before surgery in trial patients is feasible and acceptable to the majority of patients to whom it 
was offered. Among those patients who withdrew from participation  or who did not comply with 
the exercise intervention, it has been suggested that if the intervention were to be offered to 
patients as a part of the standard care pathway rather than as an optional extra, e.g. as part trial 
participation, more patients might have been inclined or persuaded to comply with a structured 
activity program as a requirement of treatment.  
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Larger collaborative trials, such as the Wesfit trial (The Wessex Fit-4- Cancer Surgery Trial) lead 
by Professor Sandy Jack of Southampton University Hospitals that started in March 2018 with the 
aim to recruit 1560 participants, are needed to confirm the results presented in this feasibility 
study (The Wessex Fit-4-Cancer Surgery Trial - Full Text View - ClinicalTrials.gov)  
 
In the design of the Pre-EMPT trial, it was recognised that the reversal of chemotherapy 
deconditioning during NAC was an unrealistic goal, however, the exercise intervention as 
reported in this thesis did result in blunting of the chemotherapy-associated fitness decline over 
a period of only 8-9 weeks in those undertaking the intervention compared to those in the 
Control group. This is a positive outcome for patients who experience the omnipresent 
deleterious effects of chemotherapy including lethargy and physical decline as a result of 
treatment. Were a larger ‘window of opportunity’ available prior to commencement of 
chemotherapy, one might expect to achieve a greater degree of protection against treatment-
induced reduction in patient fitness. The NHS target of ‘time to treatment with associated 
penalties for breaching the ‘treatment start date’ after 62 days of diagnosis is a limiting factor in 
this regard. 
 
Previous studies have all reported reduction in muscle mass concomitant to chemotherapy 
treatment. Chemotherapy treatment is also reported to be associated with reduction in VO2peak. 
Furthermore, increased body mass is also linked to reduced VO2peak.  
In this study’s Control group, there was a greater reduction in VO2peak following NAC compared 
to  the Intervention group. In the same group there was small median weight gain between 
Baseline to Post-NAC with marked deterioration in muscle mass and accompanying increase in 
fat mass observed on CT imaging. Together, these factors are likely to have contributed to the 
greater chemotherapy-associated decline in Post-NAC VO2peak in the Control group. This data 
corroborates with previous studies.  
However, the data from the Intervention group contrasts with previous findings. Amelioration of 
physical deterioration during NAC coincided with an increase in overall improvement in body 
composition viz. an increase in the Fat Free Mass (muscle mass) in the Intervention group. 
Patients in the Intervention group remained largely weight stable or showed  minimal median 
decrease in body mass. The increased activity levels in the Intervention group appear to be 
concomitant with increased muscle mass. Increased muscle mass/ Fat Free Mass - through 
participation in a structured exercise program- with weight stability, in turn logically supports 
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blunted deterioration in VO2peak indicating a causative role in the blunting of physical fitness 
deterioration during NAC. There appears therefore to be a positive correlation between the 
reduction in sarcopenia (relative and overall improvement in Fat Free Mass), with mitigating 
chemotherapy-associated deconditioning. This observation is supported by studies showing that 
greater total active muscle mass recruited during exercise results in elevated VO2peak. 
 
An additional positive impact of the intervention also lends itself to greater compliance with the 
exercise program. The improved body composition appeared commensurate with improved 
physical ability and wellbeing in the Intervention group.  This in turn, appeared to support and 
enable the participants in the Intervention group to maintain, or increase, activity levels despite 
the deleterious effects of chemotherapy. This finding is opposite to that generally described 
amongst patients undergoing peri-oncology treatment. 
 
Further to the above, the objectively assessed increase in Fat Free Mass and reduction in visceral 
fat, and improved  visceral/subcutaneous fat ratio, in the intervention group further supports the 
suggestion that exercise improves body composition with subsequent improvement in the 
regulation of inflammatory and immune systems. The mechanisms for this control appear to be 
related to the influence of inflammatory cytokines, mainly Interleukin-6, TNFa and MCP-1, and 
the immune system through T lymphocyte activation, including Natural Killer (NK) cells. IL-6 
activation from muscle contraction is reported to inhibit the pro-inflammatory activity of TNFa 
and mobilises the NK cells that may thereby assist in regulating inflammation and release of 
tumour growth factors in the TME. There is an additional increase in activation of the immune 
response through increased T lymphocyte activity despite immune-suppressive treatments. 
These observations are in contrast to the current body of knowledge and are therefore suggestive 
of the resultant physical benefits of the exercise intervention. 
 
Conversely, a lack of exercise resulted in increased weight, increased visceral fat and reduced 
muscle mass in the Control group, leading to increased inflammation and suppression of T 
lymphocyte activity  in the TME. Increased adipose tissue, and particularly visceral fat, 
exacerbated inflammation and the release of pro-inflammatory cytokines such as IL-6 and TNFa, 
while cell migration is dysregulated through increased levels of MCP-1. Together these 
inflammatory markers are related to reduced cancer control and increased risk of cancer relapse. 
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These findings correlate with current literature reporting cancer-associated sarcopenia and 
cancer treatment-related immune-suppression. 
The improvements in body composition through exercise participation appear to support 
inflammatory and immune regulation resulting in improved cancer control by the body. This 
correlates with observations in animal models but there is as yet little evidence in human 
subjects. 
 
Evaluating the clinical outcomes of the patients in the trial,  the majority of patients in both 
groups, there were either no post-op complications or complications that were limited to 
pharmaceutical intervention only. Two patients in the Intervention cohort required surgical 
intervention and resultant escalation of care but the recorded complications were more likely to 
be surgically related that to have been affected by the fitness status of the 2 patients. Three 
patients in the Control group experienced post-surgery complications that required 
radiological/surgical intervention without anaesthetic. It is difficult to ascertain whether these 
complications may or may not have been associated with fitness or the numerous confounding 
variables to which a patient is exposed during the in-hospital surgical period. Overall, the 
complication rate in both groups was lower than the national average of 38% after 
oesophagectomy (National Oesophago-Gastric Cancer Audit, 2017). The reporting and grading of 
post-op complications is an area currently under scrutiny and international collaborative 
research. There is clearly a need for standardised, clinically useful, and practically measurable 
data collection and reporting, to be able to make meaningful conclusions in this area 
 
Median hospital length of stay (LOS) following surgery was comparable in the Control and 
Intervention cohorts, respectively. Post-operative discharge from hospital after oesophagectomy 
is subject to approval by a number of different teams and processes including, but not limited to, 
dieticians; physiotherapists; Care of the Elderly teams; available care at home; patient confidence 
in being able to cope away from the care of hospital staff; procedural delays in post-radiology 
tests. Both groups, however, had a LOS below the national average. A satisfactory outcome, but 
difficult to relate directly to exercise/fitness differences between the two groups with the small 
numbers in this analysis. 
 
All patients in the trial who were prescribed adjuvant chemotherapy or chemoradiotherapy 
started their post-operative treatment. Some patients experienced delays to commencing 
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treatment but the median time to starting treatment after surgery was similar in both groups. 
The range for starting adjuvant treatment was slightly lower in the Intervention group than in 
the Control group. This is a positive result in both groups. Larger numbers and specific data points 
would be required to suggest a link in an exercise intervention with uptake and completion of 
adjuvant treatment protocols. 
 
Starting from diagnosis,  there is national and international increased focus on mental health 
strategies and patients living ‘with and beyond cancer’. More patients are surviving cancer 
treatments. Those same treatments result in significant changes to patients, their general 
health, financial circumstances, ability to work and function within families and social settings. 
In this study, limited results were achieved however the improved Mental Wellbeing achieved 
in the Intervention group would support an early introduction of exercise into the cancer 
treatment pathway.  
 
The unexpected and most notable outcome of this thesis was the improved cancer control and 
pathological tumour response to chemotherapy in the Intervention group. To the author’s 
knowledge, this is the first reported series of data demonstrating pathological evidence of 
tumour response to NAC in patients with operable oesophageal adenocarcinoma while 
undertaking a structured exercise program. 
The results from the studies presented in this thesis demonstrate the pathological evidence of 
improved tumour and lymph node regression after NAC in patients undertaking a structured 
exercise program. Tumour and lymph node downstaging through the introduction of NAC 
strategies has resulted in the single largest improvement in survival and disease control in 
oesophageal adenocarcinoma in the past 20 years. With the evidence of enhanced response to 
chemotherapy resulting in cancer reduction/control in both tumour and lymph nodes through 
the introduction of exercise as a prehabilitation concept (i.e. from diagnosis through neo-
adjuvant chemotherapy), it would seem that introducing structured exercise programs to 
patients on a peri-operative pathway may result in the next incremental shift towards improved 
cancer outcomes. 
 
The combined interactions of a structured physical activity program supporting improved muscle 
mass that underpins blunting of chemotherapy-associated fitness deterioration, while 
synchronously reducing visceral fat and the associated pro-inflammatory responses but 
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supporting immune function in patients undergoing immune-suppressive chemotherapy has not, 
to the authors knowledge, been previously described. 
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Figure 11--1 Intervention Cohort- Exercise in cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11-2 Control Cohort – Standard care pathway 
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In research and discovery, it has often been the unexpected which turns out to be the ‘game-
changer’ – discovery of Corn flakes by the Kellogg’s brothers, Greatbatch’s pacemaker, Benoit’s 
pre-mammalian therapsids and of course accidental discoveries that have altered the course of 
medicine such as Flemming, Jenner, Papanicolaou and Richet, to name but a few. 
In this thesis, ‘unexpected’ result of improved pathological tumour response to chemotherapy 
may turn out to be the ‘game-changer’ in future treatment of oesophageal adenocarcinoma. 
Early indicators in a prehabilitation program during neo-adjuvant chemoradiotherapy in 
colorectal cancer treatment indicate that this may be applicable to multiple tumour groups (West 
et al., 2019) . 
 
Further clinically relevant differences that have been uncovered in patients undertaking exercise 
intervention in the present thesis, include: 
• Improved tumour and lymph node regression after neo-adjuvant chemotherapy 
• Improved body composition, especially a decrease in visceral fat and an increased 
muscle mass, with resultant metabolic improvements 
• Statistically significantly increased TLC activation and enhanced immune function 
• Improved inflammation regulation, associated with greater control of TME 
 
The anticipated result of lessened levels of deconditioning during chemotherapy has been 
confirmed and potential mechanisms have been described.  
 
The much sought after reduction in post-operative complications and reduced length of stay 
requires further trials, clear variable definitions, and greater numbers to confirm anticipated 
effects.  
 
Limitations and future directions 
While the overall results of this feasibility trial are promising, there are limitations in a trial of this 
nature especially within the time constraints of a PhD program.  
Some of these limitations include: trial design, accessibility to funding streams , small numbers 
of participants, short period of follow-up and,  lack of patient compliance and actigraphy data. 
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The trial was designed as a geographical cohort-controlled trial largely in adherence of funding 
limitations, imposed travel restrictions by local authorities and access to limited numbers of 
patients undergoing the relevant surgery at a single-centre. Furthermore, as a feasibility study, 
the trial was not powered to definitively answer questions other than feasibility of the 
intervention. 
 
In future research, a trial of this nature would be improved by reducing potential bias through 
use of a Randomised Control Trial (RCT) design. To enable a RCT in this patient group, larger 
numbers of participants would also be required through a national, multi-centre trial, adequately 
powered to validate some of the points raised in this body of work. Adequate funding sources 
would be required to be accessible, to support research within exercise in cancer and exercise in 
health provision, generally. A national, multi-centre trial would support inclusion of greater 
numbers of participants to ensure robust datasets to provide generalisability of the outcomes 
presented. 
 
Data from future studies would be improved by including a longer follow-up period of patients 
to provide a clearer, objective view of the longer term benefits of the intervention. The data 
collection activity in the first 4 major time-points of the trial would be useful in the later stages 
of the patient’s treatment pathway. These would assist in informing clinical decisions based on 
physical, physiological and psychological aspect of patient’s treatment and in longer term ‘living 
with and beyond cancer’. 
 
This thesis suggests that the mechanism of blunting the deleterious effects of chemotherapy are 
through improved body composition, especially improved muscle mass. The inclusion of 
objective actigraphy data from wearable Fitbit devices would have been of great benefit to the 
reliability and validation of the data presented. This would be an important consideration in the 
design and implementation of future trials of this kind. 
 
The results of larger, randomised clinical trials have the potential to significantly alter the clinical 
treatment planning of patients diagnosed with oesophageal adenocarcinoma. If the benefits of 
a structured exercise intervention during cancer treatment as reported in this thesis can be 
validated by larger trials, there would potentially be a significant impact on the existing treatment 
options for newly diagnosed, and arguably all, oesophageal cancer patients. Inclusion of easily 
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accessible, structured exercise programs could be included into patients’ hospital visits with little 
adjustment to treatment schedules but with potentially clinically significant results to cancer 
treatment. Physical therapy is available at most large cancer treatment centres that would enable 
patients to access specialist support. 
However, if similar programs were to be introduced in the NHS, cost-analysis would be required 
to compare and offset the benefits of tumour regression and impact on long-term treatment 
strategies versus relatively inexpensive introductions of structured exercise prehabilitation 
programs. Appropriate out-patient and in-patient facilities, as well as suitably qualified staff with 
appropriate training, would also require investigation and cost analysis.  
What has been shown is that exercise during pre-surgical cancer treatment is feasible, acceptable 
and has multi-faceted significant impacts on cancer treatment outcomes. Cancer patients who 
participate in structured exercise programs benefit physically, physiologically, psychologically, 
pathologically, and immunologically. 
There is also the potential that patients previously considered to be non-operable at diagnosis, 
might be offered an exercise intervention with the aim of downstaging the cancer and improving 
operability – considered to be the gold standard treatment. This is an area of investigation which 
could make a substantial difference to the physical and psychological survival of the increasing 
numbers of patients diagnosed with advanced-stage disease, especially in the UK. 
Finally, if the results presented here and in future validation studies were to be substantiated, 
then prevention of cancer through participation in structured exercise should be a further area 
of research. Studies of this nature would require national support for long term, population-
based trials.  
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Chapter 12 Conclusion 
 
The benefits of exercise in the general population are well recognised. The results of the Pre-
EMPT clinical trial, presented in this thesis, provide evidence that a structured exercise program 
during neo-adjuvant chemotherapy is not only feasible but physically, psychologically, 
metabolically and physiologically beneficial in patients undergoing treatment for operable 
adenocarcinoma of the oesophagus and gastro-oesophageal junction. 
This is the first reported evidence of improved tumour and lymph node response to neo-adjuvant 
chemotherapy through a structured exercise program in oesophageal adenocarcinoma. The 
results are from a small group of patients undergoing a non-randomised trial and should be 
viewed caution until further trials validate these unique findings. However, the impact for 
patients and clinicians is potentially significant and warrants further investigation. 
The mechanisms of reduced inflammation, improved immune function and optimised body 
composition, through which the tumour and lymph node downstaging has been achieved, is 
hypothesis generating and worthy of further clinical trials, and in other cancer types. 
The evidence presented in this analysis, provides a rationale to offer a structured exercise 
program as standard care to patients undergoing treatment for oesophageal cancer. There is also 
the possibility that exercise programs, with the associated control of the TME, may result in more 
cancers becoming down-staged and therefore operable, thereby providing more patients with 
enhanced cancer treatment. 
It is proposed that structured exercise programs should be offered within the out-patient 
department for the convenience and improved access to patients undergoing oncological 
treatment. Appropriate instruction, support and encouragement will likely improve patient 
participation and compliance with prescribed exercise protocols. 
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Appendix A. Exercise Prehabilitation Program 
 
4 Week, 30 minutes Progressive Walking Programme 
Week 1 
SESSION 
1 
30 minutes moderate walk including; 10 x (30s hard walk 
with 1min 30s easy) 
 
SESSION 
2 
30 minutes moderate walk including; 2 x (5 x 1 minute 
hard walk with 1 minute easy) 5 minutes between sets 
 
SESSION 
3 
30 minutes moderate walk including; 2 x (10 x 30s hard 
walk with 1min 30s easy) 5 minutes between sets 
 
SESSION 
4 30 minutes moderate walk 
 
SESSION 
5 30 minutes moderate walk 
   
Week 2 
SESSION 
1 
30 minutes moderate walk including; 2 x (6 x 1 minute 
hard walk with 1 minute easy) 5 minutes between sets 
 
SESSION 
2 
30 minutes moderate walk including; 5 x (2 minutes hard 
walk with 1 minute easy) 5 minutes between sets 
 
SESSION 
3 
30 minutes moderate walk including; 10 x (1 minute hard 
walk with 1 minute easy) 5 minutes between sets 
 
SESSION 
4 30 minutes moderate walk 
 
SESSION 
5 30 minutes moderate walk 
   
Week 3 
SESSION 
1 
30 minutes moderate walk including; 2 x (10 x 30s hard 
walk with 1 minute 30s easy) 15 minutes between sets 
 
SESSION 
2 
30 minutes moderate walk including; 5 x (3 minutes hard 
walk with 2 minutes easy) 10 minutes between sets 
 
SESSION 
3 
30 minutes moderate walk including; 10 x (1 minute hard 
walk with 1 minute easy) 10 minutes between sets 
 
SESSION 
4 30 minutes moderate walk 
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SESSION 
5 30 minutes moderate walk 
   
Week 4 
SESSION 
1 
30 minutes moderate walk including; 3 x (5 x 30s hard 
walk with 1 minute 30s easy) 5 minutes between sets 
 
SESSION 
2 
30 minutes moderate walk including; 10 x (2 minutes 
hard walk with 1 minute easy) 10 minutes between sets 
 
SESSION 
3 
30 minutes moderate walk including; 15 x (1 minute hard 
walk with 1 minute easy) 
 
SESSION 
4 30 minutes moderate walk 
 
SESSION 
5 30 minutes moderate walk 
   
 
N.B. easy = able to hold full conversation; moderate = brisk walking, concentrating to maintain 
pace; hard = fast/power walking 
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Appendix B. Scientific Abstract 
June 2019 Medicine & Science in Sports & Exercise 51(Supplement):427 
DOI: 10.1249/01.mss.0000561780.97589.3d 
FEASIBILITY OF EXERCISE PREHABILITATION DURING NEO-ADJUVANT CHEMOTHERAPY IN OESOPHAGO-GASTRIC 
CANCER SURGERY 
 
Janine Zylstra1,2, Andrew Davies1,3 , Jim Pate4, Gemma Tham1, Nick Maisey1, Cara Baker1, Mark Kelly1, James 
Gossage1,3, Mike Browning5, Greg Whyte2,4,6 
1. Guy’s and St Thomas’ NHS Foundation Trust Hospitals, London, UK 
2. Liverpool John Moore’s University, Liverpool, UK 
3. King’s College London, London, UK 
4. Centre for Health and Human Performance, London, UK 
5. Maidstone Hospital, Maidstone, UK 
6. Research Institute for Sport & Exercise Science, Liverpool, UK 
 
PURPOSE: To determine the feasibility and potential benefits of patients, diagnosed with operable gastro-
oesophageal cancer, undertaking a structured-exercise cancer prehabilitation program (prehab) during NAC versus 
patients on a standard care pathway. 
METHODS: Patients were enrolled in a prospective, cohort-controlled trial. 
Prehab was based on World Health Organisation (WHO) ‘recommended levels of physical activity for adults over 
the age of 18’. 
Cardiopulmonary exercise tests (CPEX) was performed at 4 time-points:  
1. Baseline/pre-NAC 
2. Post-NAC 
3. Before surgery 
4. After surgery 
Participants wore wearable tracker devices. CPEX variables analysed included anaerobic threshold (AT) and peak 
oxygen uptake (VO2peak). Clinical and pathological data variables were recorded. 
RESULTS: 
At time of writing, 25 male and female patients, aged 25 – 78years, had participated in the study; 22 had undergone 
surgery. 
Mean baseline AT in the prehab group was 17.57+-3.35SD (range10.77- 20.94; n=10) ml/kg/minute, compared to 
15.19+-3.57SD (range 11.10 -22.90; n=12) ml/kg/minute in the control group. 
Mean baseline V02peak achieved was 27.55+-5.63SD (range 15.18 – 36.83) ml/kg/minute and 23.39+-4.06SD (range 
18.75- 29.94) ml/kg/minute, respectively. 
Mean values of AT and VO2peak between the groups pre-surgery were of little scientific value. However, DVO2peak 
in individual patients showed a trend towards improvement in the prehab cohort. 
Post-surgery values decreased markedly in both groups:  
Mean AT prehab decreased to 13.46+-2.29SD (range 10.54-15.91) ml/kg/minute versus 13.10+-2.60SD (range 10-
18.4) ml/kg/minute in control group. 
Mean VO2peak reduced to 20.33+-4.94 (range 14.01-26.81) ml/kg/minute compared to 19.56+-2.74SD (range18.00-
24.76) ml/kg/minute respectively. 
CONCLUSION: Cancer prehabilitation during NAC is feasible. Recovery of peak oxygen uptake shows an 
improvement trend in patients undergoing prehab during and after NAC. Post-surgery mean AT and VO2 values 
confirm physiological stress in patients undergoing high-risk, intra-thoracic and intra-abdominal oesophagectomy. 
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Appendix D. Inflammatory and Immunity Marker – Full Results 
Table 9-1 Immunity Markers - percentage change 
Value change (%) Control group Intervention group p-
values   N Mean (SD) Range N Mean (SD) Range 
CD3 (cells/uL)         
Baseline to Post-NAC 12 4.53 (25.67) (-23.00-63.41) 11 34.26 (36.58) (-16.78-111.57) 0.03 
Baseline to Pre-surgery 13 13.60 (44.09) (-25.42-119.67) 13 -4.53 (35.46) (-70.88-75.11) 0.26 
Baseline to Pre-
adjuvant 
12 5.57 (42.66) (-25.07-136.31) 11 -25.55 (26.08) (-76.75-1.46) 0.05 
CD4 (cells/uL)         
Baseline to Post-NAC 12 9.36 (37.90) (-26.30-112.17) 11 42.08 (51.40) (-22.45-179.45) 0.1 
Baseline to Pre-surgery 13 20.22 (51.52) (-20.81-164.09) 13 1.47 (46.75) (-70.81-130.48) 0.34 
Baseline to Pre-
adjuvant 
12 1.24 (46.24) (-32.21-140.95) 11 -27.06 (30.09) (-93.41-50.34) 0.13 
CD8 (cells/uL)         
Baseline to Post-NAC 12 0.98 (19.69) (-23.03-50.89) 9 29.41 (31.19) (2.82-89.66) 0.03 
Baseline to Pre-surgery 13 10.91 (40.09) (-30.42-83.98) 10 -7.98 (29.82) (-72.99-30.63) 0.23 
Baseline to Pre-
adjuvant 
12 11.61 (40.62) (-22.66-133.85) 10 -25.97 (30.43) (-77.59-15.54) 0.03 
IGG (g/L)         
Baseline to Post-NAC 14 -25.41 (14.06) (-51.03- -3.78) 12 -27.74 (10.08) (-41.17-8.91) 0.64 
Baseline to Pre-surgery 13 -6.09 (11.42) (-27.57-12.19) 13 13.20 (13.14) (-32.01-9.20) 0.15 
Baseline to Pre-
adjuvant 
12 15.38 (23.03) (-14.06-62.52) 11 -0.09 (18.22) (-25.05-22.94) 0.09 
IGA (g/L)         
Baseline to Post-NAC 14 -12.70 (12.84) (-37.74-4.28) 12 -22.80 (15.41) (-45.03-8.41) 0.08 
Baseline to Pre-surgery 13 -7.44 (26.02) (-70-33.69) 13 -11.90 (16.43) (-37.61-15.49) 0.61 
Baseline to Pre-
adjuvant 
12 17.06 (15.75) (-10.38-44.92) 11 11.96 (55.22) (-30.99-167.27) 0.77 
IGM (g/L)         
Baseline to Post-NAC 14 -33.48 (10.77) (-51.16- -10.53) 12 -27.07 (8.08) (-44.72- -11.11) 0.1 
Baseline to Pre-surgery 13 -11.00 (18.57) (-40.31-20) 13 12.21 (10.51) (-27.33-4.35) 0.84 
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Baseline to Pre-
adjuvant 
12 18.45 (27.27) (-38.10-68.57) 11 -7.48 (17.65) (-40.49-20.59) 0.01 
 
 
Table 9-2  Inflammatory Markers - percentage change 
Value change (%) Control group Intervention group 
p-
values 
  N Mean (SD) Range N Mean (SD) Range 
IL-1a (ng/L)         
Baseline to Post-
NAC 
11 -3.18 (24.37) (-45.83-43.75) 10 -17.17 (36.87) (-65.65-9.13) 0.23 
Baseline to Pre-
surgery 
12 -30.09 (34.52) (-60.61-60.87) 12 -11.80 (37.74) (-70.23-63.16) 0.23 
Baseline to Pre-
adjuvant 
10 0.13 (33.80) (-47.83-58.82) 9 -31.48 (35.01) (-83.21-0.00) 0.06 
IL-1b (ng/L)         
Baseline to Post-
NAC 
11 -9.78 (21.59) (-61.02-17.32) 10 -9.46 (64.01) (-75.51-126.09) 0.99 
Baseline to Pre-
surgery 
12 -45.02 (36.24) (-71.95-55.88) 12 2.81 (56.41) (-72.13-94.06) 0.02 
Baseline to Pre-
adjuvant 
10 -0.35 (24.13) (-4.31-50.00) 9 14.01, (54.60) (-70.49-84.62) 0.5 
IL1RA (ng/L)         
Baseline to Post-
NAC 
11 7.65 (47.70) (-57.35-97.80) 10 -9.96 (33.97) (-58.80-44.25) 0.35 
Baseline to Pre-
surgery 
12 10.22 (83.35) (-68.39-246.39) 10 -27.06 (34.34) (-70.69-44.21) 0.18 
Baseline to Pre-
adjuvant 
10 14.04 (56.32) (-51.84-137.93) 8 
22.82 
(120.60) 
(-83.54-297.95) 0.85 
IL-2 (ng/L)         
Baseline to Post-
NAC 
11 1.99 (29.19) (-56.47-52.43) 10 1.93 (73.94) (-70.69-195.10) 1 
Baseline to Pre-
surgery 
12 -22.21 (46.30) (-70-110.53) 12 -14.76 (32.12) (-77.35-30) 0.65 
Baseline to Pre-
adjuvant 
10 12.57 (32.68) (-21.25-84.41) 9 23.53 (32.28) (-80.42-0.00) 0.03 
IL-4 (ng/L)         
Baseline to Post-
NAC 
11 -2.18 (5.79) (-19.05-0.00) 10 1.95 (27.49) (-57.19-52.58) 0.65 
Baseline to Pre-
surgery 
12 -0.28 (22.32) (-23.02-68.63) 12 -3.86 (20.96) (-67.56-20.09) 0.69 
Baseline to Pre-
adjuvant 
9 2.29 (6.86) (0.00-20.59) 8 10.39 (26.13) (-67.56-16.51) 0.18 
IL-6 (ng/L)         
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Baseline to Post-
NAC 
11 
126.41 
(107.59) 
(-53.14-282.39) 10 27.93 (97.02) (-55.94-275.00) 0.04 
Baseline to Pre-
surgery 
12 36.63 (41.26) (-50.17-119.77) 12 
18638.20 
(64491.17) 
(-81.64-223425) 0.34 
Baseline to Pre-
adjuvant 
10 
111.09 
(216.74) 
(-71.62-650.00) 9 
22.16 
(102.24) 
(-97.41-261.33) 0.27 
IL-8 (ng/L)         
Baseline to Post-
NAC 
11 7.59 (56.13) (-66.85-154.55) 10 1.04 (46.17) (-72.78-82.47) 0.77 
Baseline to Pre-
surgery 
12 62.11 (192.19) (-58.22-657.35) 12 
75.20 
(217.21) 
(-63.07-696.70) 0.88 
Baseline to Pre-
adjuvant 
10 -32.43 (31.81) (-68.73-32.50) 9 20.90 (89.14) (-87.50-138.69) 0.12 
IL-10 (ng/L)         
Baseline to Post-
NAC 
11 11.34 (30.58) (-22.64-64.29) 10 -4.69 (37.40) (-61.88-68.75) 0.29 
Baseline to Pre-
surgery 
12 -37.05 (28.92) (-72.57-39.53) 12 
443.04 
(1569.05) 
(-83.43-
5424.32) 
0.3 
Baseline to Pre-
adjuvant 
10 -28.07 (23.67) (-69.03-2.44) 9 -23.19 (28.91) (-69.06-35.42) 0.69 
VEGF (ng/L)         
Baseline to Post-
NAC 
11 51.79 (99.54) (-67.10-300.34) 10 10.51 (62.09) (-60.27-149.58) 0.27 
Baseline to Pre-
surgery 
12 44.42 (103.38) (-56.26-313.70) 12 
36.74 
(101.27) 
(-51.85-238.39) 0.86 
Baseline to Pre-
adjuvant 
10 5.41 (50.07) (-58.10-82.43) 9 
15.60 
(111.22) 
(-72.82-269.41) 0.81 
INF-y (ng/L)         
Baseline to Post-
NAC 
11 
223.64 
(562.36) 
(-50-1900) 9 
57.24 
(140.13) 
(-80.60-300) 0.36 
Baseline to Pre-
surgery 
9 
3336.19 
(9961.65) 
(-84.29-29900) 10 0.00 (59.56) (-88.81-150) 0.34 
Baseline to Pre-
adjuvant 
10 
261.43 
(461.15) 
(-85.71-
1300.00) 
9 
73.62 
(267.82) 
(-88.08-781.36) 0.3 
TNFa (ng/L)         
Baseline to Post-
NAC 
11 28.31 (74.51) (-30.99-233.33) 10 -1.77 (33.23) (-53.03-45.45) 0.25 
Baseline to Pre-
surgery 
12 27.76 (58.79) (-34.62-125.64) 12 
51.21 
(159.12) 
(-50.89-455.93) 0.64 
Baseline to Pre-
adjuvant 
10 26.40 (38.20) (-26.14-82.22) 9 1.10 (40.01) (-46.23-75.76) 0.18 
MCP-1 (ng/L)         
Baseline to Post-
NAC 
11 
163.69 
(193.53) 
(-45.56-482.08) 10 52.11 (58.18) (-34.01-174.16) 0.09 
Baseline to Pre-
surgery 
12 58.59 (119.43) (-33.18-405.88) 12 
120.97 
(336.28) 
(-42.96-
1174.49) 
0.55 
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Baseline to Pre-
adjuvant 
10 32.28 (89.96) (-48.38-259.66) 9 
50.59 
(146.26) 
(-64.60-428.46) 0.74 
EGF (ng/L)         
Baseline to Post-
NAC 
11 -8.23 (152.86) (-95.21-440.00) 10 20.06 (80.48) (-62.72-176.47) 0.61 
Baseline to Pre-
surgery 
12 -53.47 (66.96) (-98.65-140) 12 
16.49 
(125.27) 
(-93.55-341.64) 0.11 
Baseline to Pre-
adjuvant 
10 
205.95 
(437.67) 
(-97.26-
1285.71) 
9 
24.93 
(157.86) 
(-87.90-411.76) 0.26 
 
 
 
 
Figure 9-2 Exemplar plot of T-Lymphocyte subset results and histogram plot CD3, CD4 and CD8 
gating 
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Appendix E. Table 10-1 Mental Wellbeing and HRQL scores 
    Controls  Intervention  
Intervention - 
Did not 
participate 
Measure Timepoint N Mean (SD) N Mean (SD) N Mean (SD) 
Mental 
Wellbeing 
Baseline  17 31.18 3.71 12 30.25 2.99 8 27.5 4.81 
  Post-NAC 13 30.08 4.61 11 30.27 3.69      
  Pre-surgery 13 32.85 2.44 11 31.27 4.65      
  
Before adjuvant 
chemo 
11 31.46 4.37 9 29.78 4.68   
 
  
  6 months post-op 10 28.9 6.05 8 31.25 3.2      
  12 months post-op 7 29.43 3.31 8 30.13 3.14   
 
  
Physical 
functioning 
Baseline  17 1.12 0.2 12 1.18 0.46 8 1.1 0.15 
  Post-NAC 13 1.35 0.3 11 1.27 0.27      
  Pre-surgery 13 1.06 0.1 11 1.24 0.72      
  
Before adjuvant 
chemo 
11 1.38 0.28 9 1.76 0.86   
 
  
  6 months post-op 10 1.48 0.74 8 1.23 0.23      
  12 months post-op 7 1.2 0.23 8 1.13 0.18   
 
  
Role 
Functioning 
Baseline  17 1.12 0.28 12 1.33 0.89 8 1.69 0.92 
  Post-NAC 13 1.46 0.52 11 1.91 0.86      
  Pre-surgery 13 1.19 0.56 11 1.5 0.98      
  
Before adjuvant 
chemo 
11 1.64 0.6 9 2 0.97   
 
  
  6 months post-op 10 1.55 0.96 8 1.19 0.26      
  12 months post-op 7 1.43 0.79 8 1.13 0.23   
 
  
Emotional 
refunctioning 
Baseline  17 1.45 0.38 12 1.55 0.51 8 1.6 0.59 
  Post-NAC 13 1.48 0.45 11 1.6 0.4      
  Pre-surgery 13 1.4 0.45 11 1.76 0.81      
  
Before adjuvant 
chemo 
11 1.22 0.3 9 1.78 1.01   
 
  
  6 months post-op 10 1.32 0.43 8 1.68 0.48      
  12 months post-op 7 1.4 0.45 8 1.55 0.59   
 
  
Cognitive 
Functioning 
Baseline  17 1.18 0.3 12 1.42 0.85 8 1.38 0.58 
  Post-NAC 13 1.42 0.45 11 1.36 0.39      
  Pre-surgery 13 1.19 0.33 11 1.46 0.76      
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Before adjuvant 
chemo 
11 1.18 0.34 9 1.61 1.02   
 
  
  6 months post-op 10 1.3 0.42 8 1.25 0.38      
  12 months post-op 7 1.29 0.39 8 1.5 0.54   
 
  
Social 
Functioning 
Baseline  17 1.38 0.52 12 1.5 0.88 8 1.5 0.71 
  Post-NAC 13 1.65 0.8 11 1.86 0.78      
  Pre-surgery 13 1.19 0.38 11 1.36 0.71      
  
Before adjuvant 
chemo 
11 1.77 0.52 9 2.06 1.07   
 
  
  6 months post-op 10 1.8 1.01 8 1.63 0.35      
  12 months post-op 7 1.29 0.49 8 1.31 0.46   
 
  
Fatigue Baseline  17 1.63 0.44 12 1.47 0.83 8 1.63 0.72 
  Post-NAC 13 2.21 0.65 11 2.06 0.71      
  Pre-surgery 13 1.44 0.46 11 2.03 0.97      
  
Before adjuvant 
chemo 
11 2.21 0.45 9 2.41 0.78   
 
  
  6 months post-op 10 2.07 0.66 8 1.88 0.53      
  12 months post-op 7 1.76 0.6 8 1.46 0.59   
 
  
Nausea Baseline  17 1.24 0.4 12 1.33 0.62 8 1.19 0.26 
  Post-NAC 13 1.46 0.52 11 1.46 0.65      
  Pre-surgery 13 1.04 0.14 11 1.64 1.1      
  
Before adjuvant 
chemo 
11 1.36 0.55 9 1.44 0.39   
 
  
  6 months post-op 10 1.25 0.43 8 1.44 0.62      
  12 months post-op 7 1.36 0.75 8 1.38 0.52   
 
  
Pain Baseline  17 1.44 0.61 12 1.46 0.87 8 1.75 0.85 
  Post-NAC 13 1.23 0.48 11 1.18 0.41      
  Pre-surgery 13 1.12 0.42 11 1.46 0.96      
  
Before adjuvant 
chemo 
11 1.64 0.64 9 2.11 0.99   
 
  
  6 months post-op 10 1.35 0.41 8 1.5 0.46      
  12 months post-op 7 1.43 0.45 8 1.38 0.52   
 
  
Dyspnoea Baseline  17 1.47 0.62 12 1.25 0.87 8 1.5 0.54 
  Post-NAC 13 1.69 0.63 11 1.64 0.81      
  Pre-surgery 13 1.39 0.51 11 1.36 0.92      
  
Before adjuvant 
chemo 
11 1.82 0.6 9 1.78 1.09   
 
  
  6 months post-op 10 1.4 0.52 8 1.25 0.46      
  12 months post-op 7 1.14 0.38 8 1.25 0.46   
 
  
Insomnia Baseline  17 1.71 0.92 12 1.83 0.84 8 2 1.07 
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  Post-NAC 13 1.85 0.8 11 1.73 0.65      
  Pre-surgery 13 1.69 0.86 11 2 0.89      
  
Before adjuvant 
chemo 
11 1.82 0.98 9 2.11 1.17   
 
  
  6 months post-op 10 1.4 0.7 8 2 0.93      
  12 months post-op 7 1.43 0.54 8 1.75 1.17   
 
  
Appetite Loss Baseline  17 1.65 0.86 12 1.67 0.99 8 1.38 0.52 
  Post-NAC 13 1.46 0.66 11 1.64 0.67      
  Pre-surgery 13 1 0 11 1.46 0.93      
  
Before adjuvant 
chemo 
11 1.82 0.87 9 2 0.87   
 
  
  6 months post-op 10 1.3 0.68 8 2 0.93      
  12 months post-op 7 1.86 0.9 8 1.75 0.89   
 
  
Constipation Baseline  17 1.29 0.47 12 1.75 0.87 8 1.75 1.04 
  Post-NAC 13 1.46 0.66 11 1.46 0.69      
  Pre-surgery 13 1.08 0.28 11 1.55 0.93      
  
Before adjuvant 
chemo 
11 1.46 0.69 9 1.33 0.5   
 
  
  6 months post-op 10 1.4 0.7 8 1.63 0.74      
  12 months post-op 7 1.43 1.13 8 1.63 0.74   
 
  
Diarrhoea Baseline  17 1.06 0.24 12 1.08 0.29 0 1 0 
  Post-NAC 13 1.54 0.66 11 1.64 0.67      
  Pre-surgery 13 1.31 0.63 11 1.64 0.81      
  
Before adjuvant 
chemo 
11 1.55 0.52 9 1.78 0.67   
 
  
  6 months post-op 10 1.3 0.48 8 1.5 0.76      
  12 months post-op 7 1.29 0.76 8 1.63 0.74   
 
  
Financial 
difficulties 
Baseline  17 1.24 0.56 12 1.67 1.07 8 1.13 0.99 
  Post-NAC 13 1.31 0.63 11 1.64 0.81      
  Pre-surgery 13 1.39 0.51 11 1.46 0.93      
  
Before adjuvant 
chemo 
11 1.27 0.47 9 1.44 1.01   
 
  
  6 months post-op 10 1.6 0.97 8 1.5 0.93      
  12 months post-op 7 1.29 0.49 8 1.38 0.52       
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